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CHAPTER I
INTRODUCTION
Denuded skin areas (e.g., partial and ful 1 thickness burns,
severe traumatic injury, various skin diseases) present problems with
respect to app 1 i cation and remova 1 of

convent_l_on_a_l_t_o_p_Lc_a_l_dosa,ge_foxms-.~~~~~-

With these problems in mind, a highly water soluble, flexible film for
topical application was developed (1-3).

The film adheres to denuded

and moist skin, dissolving quickly and releasing the active ingredient.
Both in vitro and in vivo studies were performed to evaluate
the film.

When comparing the film to commercially available topical

antimicrobial products,

~.!_!r2,.and _L!]~~methods

showed that the

fi Jm was as effective as conventional bases for mafenide and gentamicin
and more effective for silver sulfadiazine and silver nitrate.

Also,

preliminary stability and packaging studies indicated that the film, if
properly packaged and stored, has marketing potential.·
The basic unmedicated formula consists of dextran, sorbitol,
Miranol 2 MCA Modified, and water.

The major advantages of the fi Jm

are 1) fast release rates, 2) ease of application to denuded skin without
aggravation, and 3) lack of necessity for removal, hence no aggravation.
However, it is extremely sensitive to moisture and elevated temperatures
which is a major disadvantage.

Excessive humidity will solubilize the

film or make it too tacky to handle while very low humidity causes the
film to lose its flexibility.

Also, elevated temperatures remove

moisture from the film and cause it to lose flexibility much as with

2

low humidities.
This study was designed to evaluate further this new dosage form
with respect to:
1.

Modification of formula to minimize moisture sensitivity.

2.

Determination of a suitable packaging material.

3.

Determination of proper storage conditions.

4.

Determination of shelf-! ife of silver sL•Ifadiazine and
nitrofurazone dry~f~o~a~m~s~·--------------------------------------~----~

5.

Determination of a suitable sterilizing method(s).

Percutaneous

Absorptl9~

Because there are many areas of controversy surrounding the concept of percutaneous absorption, it is literally impossible to make
positive statements about all of its aspects.

Nevertheless, a review of

commonly accepted generalities does serve as a reference point for a
discussion of topical dosage forms.
Percutaneous absorption, as defined by Rothman (4), Collaizzi

(5), and Barr (6), is the penetration of substances from the outside
into the skin and through the skin into the bloodstream.

However, Blank

(6,7) states that an actual definition of percutaneous absorption is not
necessary, but rather it is more important to kno'.'l how drugs move into
and through the skin.

It is here that so many areas of controversy

arise, i.e., routes of entry, factors affecting the rate of absorption,
factors affecting the extent of absorption, and methods of evaluation.
Historically, there are three periods and, hence, three schools
of thought regarding the mechanisms of percutaneous absorption (6).
These are 1) the period up to 1877 in which it was accepted that gases
and volatile substances penetrated the skin easily; 2) 1877-1900 in which

3
Fleischer•s theory that the skin is impermeable to all substances predominated; and 3) 1900 to the present in which Fleischer•s theory has
been disproved and in which much research has been done to determine the
mechanism of and the factors affecting percutaneous absorption.

This

last period will be reviewed here.
Routes of Entry
11----------__,.B._.l,_,i_,..s_,..s'---(. 8) and Ha 1 i~(9J~c_La_Lm_t_r_aos_ep_Lde_rmaJ_erLtr_y_tbro_ugb_tbe,_ _ _ _ _ __
.?_~

corneum to be the major route because its surface area is 100 to

1000 times that of the transappendageal route.

Shelmire (10) and Gemmell

and Morrison (11), on the other hand, claim that the major route is via
the skin appendages (pilosebaceous regions and sweat glands).

They

ba~e

this on the observation that hair follicles possess preferential staining
properties, perifollicular v.1heals develop, and dyes diffuse rapidly
through the sweat glands.

~1ost

investigators (4-6,12,13) agree that both

processes are involved and that some drugs may have a greater affinity
for one route over the other.
et~

Furthermore, Scheupl in (12) and Arita

(14) state that for drugs capable of penetrating the skin, there

are two stages.

In the initial or rapid stage, the transappendageal

route is the primary method of entry and in the second or steady state
stage, the

transepider~al

route is the major method.

agree that before a route of entry comes into

play~

be released from the vehicle, transferred to the

All investigators
the drug must first

sk~n,

and then have the

ability to penetrate the skin.

When developing a topical dosage form, the investigator is ·
essentially working with three separate entities:

the skin, the

dr,.~;.

4
and the vehicle.

Separately, each p6ssesses certain properties which

affect percutaneous absorption.
entiti~s

However, in actuality, all three

necessarily comprises a skin-drug-vehicle system such that the

final effect is a composite of all the

sep~rate

factors working together.

Some of these factors such as hydration of skin, drug form, vehicle
composition, and concentration of drug in the vehicle can be altered;
others, namely those involving the anatomy of the skin p_er se, cannot
be

change~Tne

purpose of the skin is primarily that of protection and

this protective barrier must be overcome to effect percutaneous
absorption.
Skin factors affecting percutaneous absorption are related to
the structure and physical/chemical properties of the skin components.
While these properties will vary in different sites and from person to
person, some generalities seem to hold.

The major barrier to absorption

is the s. corneum with its layer of lipids (4,8,15-18).

Some feel that

the major barrier is really between the s. corneum and the dermis

(6,10,14).

However, all agree that the major barrier is electronegative

in nature and consists of keratin and other lipid materials.

Inter-

spersed throughout the s. corneum are the various appendageal ducts which
are filled with sebaceous or lipid substances.

Thus, regardless of the

route of entry, a drug must be partly soluble in lipids in order to
penetrate.

Likewise, undissociated drugs

~rd

11 penetrate well since

'
negatively charged drugs will .be repelled and positively
charged drugs
attracted and bound to the charged barrier (4,6,11,14).

Rothman (4),

however states that di·· and trivalent ions wi 11 penetrate to some extent
because they are partly lipid soluble.

Keratin, a sulfhydryl protein

which adsorbs water and other polar compounds, can potentially interact

5
to hind with various drugs further complicating the predictability of
percutaneous absorption for any drug (6).
Other skin factors affecting absorption relate to difference in
sites and the general condition of the skrn.

For example, the forehead,

presternal area, and the back demonstrate the greatest permeability.
Thicker areas such as the soles of the feet and palms of the hands are
the least permeable (8,10,19-21).

Hydration from moisture and sweat

will increase absorption because the keratin swells and becomes more
permeable and the intercellular pores become larger (4,6,8,10,13,17,20,
22-28).

Aged skin, due to atrophy and dehydration, is less permeable

(6,8,19,26) while young skin and skin of women show increased absorption,
presumably because of greater hydration and thinness (8,19).

These

statements are general and individual variation must be considered.
All of the above factors re 1at i ng to the skin do not affect
percutaneous absorption if the s. corneum is removed purposely or by
disease or traumatic insult.
eas~ly

In such instances, all drugs penetrate

and readily and this fact substantiates that the s. corneum (or

zone beneath it) is the primary barrier to absorption (L!,6,10,19,20,26,
29).
The skin factors can be altered by removal of the skin, hydration, and emulsification.
in experimental conditions.

Removal, of course, is not desirable except
Thus, it is the hydrati?n and emulsification

aspects that product developers try to attain for topical preparations.
Once a drug has crossed the major barrier, the lower layers of the
epidermis and dermis offer little resistance to absorption into the
bloodstream and subsequent pharmacological affect.

The .factors which now

enter the picture are protein binding, receptor specificity, rate of

""~-

6
metabol

i~

inactivation, and rate of excretion (30).

Two fundamental processes must occur before a topical drug can be
effective.

First, the drug mus(be released in therapeutic concentra-

tions from the vehfcle at an adequate rate and then the drug must be
capable of penetrating the skin.

Thus, the product developer must employ

methods to evaluate the rate and extent of release and
absorption.

subseq~u~e~n~t_________________

Wurster and Seitz (31) have stated that vehicles which are

porous, i.e., have a high surface area to weight ratio, will have faster
dissolution rates and hence, faster release rates.
~

In addition, Marcus

(32) showed that the release of an active ingredient is not

infiuenced by but is independent of the presence of other noninteracting
drugs, since the thermodynamic activity of the drug in a vehicle is the
only significant factor governing rate of release and absorption.

Thus,

they concluded that incorporation of two or more noninteracting drugs
into a vehicle will allow decreased doses and side effects resulting in
a less expensive product.
Topical products can be evaluated by

(6,7,11,21,26,27,33,34).

~L!!~

and in vivo methods

In vitro methods include I) diffusion without

a membrane using chemical-physical and microbiological methods; 2)
diffusion through a membrane using chemical-physical and microbiological
mefhods; and 3) tracer methods using radioactive substances, dyes, and
fluorescent compounds.
release rates.

These methods are mainly used to evaluate

Because the continuous phase in the diffusional media

is aqueous, direct correlation with i_l:l_vivo results is not possible.
Nevertheless, they do provide an excellent guide for determining the
relative effectiveness of a vehicle (4,6,11 ,21 ,26,27,33-37).

)

7

Diffusion methods without a membrane usually employ an agar gel
in a tube or plate.

For chemical-physical methods, the agar media may

contain a reagent that produces a color when in contact with the drug
(e.g., salicylic acid with ferric chloride).

The rate and extent of

release is calculated based on the diameter of the color zones .in
millimeters plotted against time.

This method is simple and inexpen-

sive, is not time consuming, and does not require precautions such as

good quantitative method and only drugs which will produce color
react ions can be used (7, ll ,21 ,26 ,33-36).
Microbiological diffusion employs nutrient agar medium which is
seeded with a specific test microorganism.

Release of antimicrobial

drugs can then be evaluated by measuring the zones of inhibition.

The

diameter of the zones in millimeters is a measure of the release rate.
This method provides a good procedure to evaluate release of antimicrobials (7,11,21,26,33-36,38-40).

Shelmire (10), Billups and Patel

(21), Gemmell and Harrison (11), Zheutlin and Fox (41), and Scheuplin
(12) all state that a topical antimicrobial drug does not need to
penetrate the skin; hence, if a microbiological procedure indicates that
the drug is released sufficiently to inhibit microbial growth, this
method of evaluation is very useful for these agents.
recognize the fact that the

~skin,

However, they do

because of its different composition

from an aqueous agar gel, may alter the extent of release such that
therapeutic concentrations may not reach the site of action in vivo.
Diffusion methods using a semipermeable

membran~

such as a

dialysis cell or agar tube covered with a membrane provide two distinct
advantages over nonmembrane procedures.

These methods l) resemble a

8
more true-to-life situation in which the skin is the membrane and 2)
allow quantitative analysis of the receptor chamber using various chemical methods.

For chemical-physical methods, mahy types of diffusion

models using a membrane have been devised.

Some employ very elaborate

and sophisticated instrumentation while others
forward (41-53).

are·sf~ple

and straight

Membranes made of sheep bladder or isolated skin have

been claimed to resemble true skin better; however, :me must realize
that there is a great difference between dead and living epidermis (6).
The basic apparatus uses two chambers separated by a membrane.

One

chamber is filled with the receptor medium (usually aqueous) while the
other contains an accurately measured quantity of the drug product.

At

various time intervals, exact quantities from the receptor med1um are
removed for analysis by any satisfactory method (21 ,45).

The disadvan-

tages of this method are that nondialyzable substances cannot be
evaluated and if the product chamber contains a liquid medium, drugs
in which the vehicle is highly soluble cannot be used (43).
For microbiological studies, an agar tube seeded with the microorganism is usually covered with a membrane and the product placed on
top.

Zones of inhibition are then measured to evaluate release (42).

The advantage this procedure has over the nonmembrane method is that
it resembles the true situation a 1 ittle more closely.

Again,

quantification is not very good.
Of the three tracer methods, the use of radioactively labelled
compounds is best.

While dyes and fluorescent compounds are easily

analyzed, the dye or fluorescent compound may not remain with the drug
or thciy may alter the physical-chemical properties of the drug (6).
However, labelling of a drug with a radioactive element can provide

9
evaluation of almost all therapeutic agents;
only major limitation.

trained personnel is the

Nevertheless, the use of radioactive label ling

is by far the best method to quantitatively evaluate the release and
absorption of drugs (6,7, 11,21 ,26,27 ,33-36).
The indiscriminate use of in vitro physical models and subsequent
calculations can lead to misleading and erroneous results with respect to
rate and extent of release (54).

Chowhan and Poulsen (54), in their

critical review, emphasize that the mathematical formulas to calculate
release rates differ for solutions, suspensions, and semisolids.
Furthermore, one must take into consideration the number of therapeutic
agents present, changes in vehicle composition after application, and
other parameters when devising an in vitro model.
For obvious reasons, in vivo methods should be used to evaluate
a drug product, especially with respect to absorption, metabolism, and
excretion (6,7,11 ,26,27,33).

Methods used include measuring of a

physiological response such as vasoconstriction, analysis of body fluids
such as urine, loss of drug from the skin surface, histological procedures, and tracer methods.

While in vivo methods are preferable, they

do possess certain disadvantages.

If lower animals are used, direct

correlation with humans cannot be made; if humans are used, expense,
cooperation, control factors, and health hazards become problems.
Physiological responses rely greatly on subjective evaluation
\

(6,7,33) although McKenzie and Stoughton (55), McKenzie (56), and
Vickers (57) developed acceptable vasoconstriction tests for corticesteroids.

Washitaki et al. (18,29) used the vasoconstriction test for

steroids and a vasodilatation test for carbinoxamine and obtained
acceptable results for absorption.

Rate of excretion, storage tendencies,

10
rate of entry into and out of the bloodstream, and rate of metabolism
must be known for tissue analysis methods; otherwise, one must estimate
time intervals for analysis (6,7,33).

Using loss of drug from the skin

is probably the worst in vivo method of all (6,7,33).

In this method,
~-

the drug product is removed from the skin and analyzed for drug concentration.

....;--

The difference at the time of application and at the time of

removal is considered to be absorbed.

However, the pitfalls in such a

completely, the drug may have complexed with skin components and not
been absorbed, and the quantities one is working with are so small that
errors in analysis are likely.

Histological studies are not very

valuable from a quantitative viewpoint (6,7,33).

Disadvantages of dyes

and fluorescent tracers were mentioned earlier along with some limitations
of radioactive tracers.

Other disadvantages of radioactive methods are

1) autoradiography indicates if a drug has reached a particular physiclogical site and now how the drug reached that site; and 2) urinary
analysis only indicates that the drug is excreted in the urine and not
the pathway into the urine.

Thus, while in vivo methods are superior to

in vitro methods, they are nevertheless only estimations and one must
take this and specific disadvantages into consideration (6,7,).
Stabi 1 i ty
Whittet (58) and Schou (59) .have defined stability of a drug

"

product as the period of time from completion of a preparation until it
no longer fulfills specifications of the pharmacopeia or until a 10% loss
in potency has occurred.

Thus, stability of a drug product is an

integral part of quality control.

A stable product implies that at

~--
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least 90% of the labeiled quantity of an active ingredient is in the
product; that each dose wil I be uniform; that the product will maintain
its appearance;. that the drug will be ~ade bioavailable; th~t the product
is safe when used properly; and that the package and recommended storage
~-

conditions will not affect the product (37,60).

A shelf-! ife of one

year is considered fair while five years is considered the maximum since
no finished product is entirely stable (60-62).

Consequently, compendia!

regulations and guide! ines for good manufacturing principles must be
followed (59,63).
Instability or degradation is caused by chemical, biochemical,
and physical factors (58,59,61,64-66).

Whittet (58) and Smith (64)

reviewed these degradation processes and methods to minimize or prevent
them.
and

Chemical and biochemical factors include oxidation, reduction,

hydrol~sis

reactions, racemization, specific biochemical reactions,

and drug-package interactions.
Oxidation is defined as the addition of electronegative atoms or
radicals or the loss of electropositive atoms or radicals.
oxygen or removal of hydrogen are usually involved.

Addition of

Air and oxygen will

cause oxidation of drugs such as oils, fats, phenols, and vitamins.

Anti-

oxidants will minimize oxidation as will removal of all air or oxygen
from the package.

The air or oxygen is usually replaced with nitrogen

or carbon dioxide, although one must be aware of pH
carbon dioxide.

~hanges

caused by

A 10° increase in temperature increases oxidation rates

two to threefold; thus, temperature control during storage is important.
Absorption of radiation such as ultraviolet or gamma rays also increases
oxidation rates.

Radiation sensitive drug products should therefore be

stored in light-resistant glass containers or laminated aluminum foil.

12

Metal ions are catalysts in oxidation reactions and these should be
complexed with EDTA or the like.
tion.

::

~

Moisture and pH also facilitate oxida-

Thus, adjustment of pH and use of moisture impermeable containers

such as aluminum laminates may be required to reduce or eliminate

-i--=_

oxidation reactions.
Reduction reactions are defined as the addition of electropositive
atoms or radicals or the removal of electronegative atoms or radicals.

common as oxidation reactions

~nd

usually involve the reduction by light

of metal ions such as gold, silver, and mercury.

Use of light-resistant

containers will usually prevent these degradative reactions.
Racemization may result in loss of potency and it obviously
involves those drugs which have only one therapeutically active
enantiomer.

Racemization requires moisture and thus, moisture impermeable

containers aid in minimizing or preventing racemization reactions from
occurring.
Degradative biochemical reactions can be caused by enzymes or
microorganisms.

Removing moisture, where possible, will prevent

enzymatic degradation.

Storage at low temperatures, use of preservatives,

and protection from moisture wiil usually eliminate microbial growth and
subsequent degradation caused by microorganisms.
Drug-package interactions such as sorption and leaching are
usual Jy associated with plastic containers.

Selection of a noninteracting

plastic or a different type of container will help prevent or minimize
these reactions.
Physical factors usually cause degradation indirectly by eliciting
one or more of the above described chemical reactions.

However, physical

~-
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factors may also directly affect drug products in a number of ways.
Moisture wi II solubilize or cause caking of hygroscopic, effervescent,
and deliquescent products while changes in humidity may cause these
products to gain or lose significant amounts of moisture.

Increased

storage temperatures might cause melting of certain drug products while
decreased temperatures lead to precipitation of biologicals or freezing
of certain dosage forms.

Further, high temperatures many times employed

during manufacturing and sterilizing methods may degrade or even char
certain drugs and packages such as plastics; similarly, radiation
sterilization destroys drugs such as atropine sulfate, heparin, and
progesterone as wel 1 as packages consisting of polyethylene and soft
glass.

Breakage, cracks, corrosion, and sealing defects of packaging

materials cause obvious instability since the drug product is no longer
protected from the environment.

Finally, formulas themselves may cause

cracking, creaming, caking, drying, and aggregation resulting in an
unstable product.

In order to assure stability, these physical factors

must be eliminated or avoided by defining proper storage conditions,
employing appropriate manufacturing and sterilizing procedures, selecting
suitable packaging materials, and using stable formulations.
While one can theoretically minimize or prevent instability
mechanisms, the product developer must nevertheless perform stability
tests to prove that the product is stable.

The tests must be performed

on the final packaged product in order to be valid (58,59).

The most

common experimental procedure involves storage at various temperatures
with or without varying relative humidities; the product is then analyzed
by various chemical or microbiological procedures as well as physical
inspection (37,39,40,61,67-76).

The method chosen for analysis is

~-

somewhat dependent on the nature of the drug.

Chemical methods such as

chromatography and photometry are the most common; colorimetry with
photometry are used for drugs which form color reactions wifh a reagent.
Agar diffusion with subsequent measurement of zones of inhibition is most
-~-

common for antimicrobial products (39,40,59,61,67).

~-

The rate of degradation for most drug products follows first
order kinetics (66,71).

That is, the concentration of the drug decreases

concentration. The basic equation for a first order reaction is
dC
- ~-- = kc where C is the concentration at time t and k is the first
dt
In order to calculate~' the equation has to

order velocity constant.

be changed via integration to a workable form as follows:
~-

J

dC

c

-k.fdt

=

(Eq. 1)

0

InC - In

c0 =

-k(t-0)

(Eq. 2)

or
In C = In

c

- kt

0

(Eq. 3)

or
log C = log

kt

c

2.303

0

(Eq. 4)

or

k

=

2.303
~t

log

c

( Eq. 5)

where C0 is initial concentration, C is the concentration at timet,
0 is initial time, i~e., time zero, and k is the specific degradation
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constant (66,71).

Once~ has been calculated, the concentration at any

timet can be calculated.

The shelf-life of a drug product can then be

predicted from performing stability tests for relatively short periods
of time, assuming that the product is still in a usable form and that
concentration is a measure of activity.
Temperature affects degradation rates as shown by the Arrhenius
equation below (59,66,70,71 ,76,77).

k

(Eq. 6)

=

or
log k = log A -

( Eq. 7)

T

where k =specific rate of degradation
-1

R =gas constant (1.987 calories degree

-1

moles

A = entropy constant
Ea

= energy

of activation

T - absolute temperature
This is the reason that most stability studies are carried out at
various elevated temperatures and then the results are extrapolated to
room temperature.

This method allows one to use relatively short storage

periods of months as opposed to uneconomical and impractical storage test
periods of one year or more.

Results of elevated temperature studies are

valid when the degradation is due only to thermal phenomena and not due
to photochemical, microbiological, freezing, or other physical factors.
For these latter

instances~

long term storage studies and the use of

appropriate order equations are required (66).
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Packaging
The function of a package is to preserve goods so that they get
to the consumer for their original intended pur·pose (65,78).
to providing mechanical and

environment~]

In addition

protection, packaging materials

must also be functional, inert, and available at a reasonable cost.
Other desirable features include lightness in weight; ease of storage,
use, and label] ing; and

aestheti~

appearance.

The packaging material

shouia----cfiS()be nonfiammabie, noncorrodabie, nontoxic, odoriess, and-be
ecologically advantageous.

Availability in various sizes, shapes, and

colors further adds utility to a packaging material.
The common types of materials used to package pharmaceut1cals
are glass, paper, plastics, and metals including aluminum foil.

The

manufacturer must select the most appropriate package for each type of
pharmaceutical; all packages possess some disadvantages.

While glass

meets the main criteria, its major disadvantages are that it is easily
broken, not as versatile as plastics and aluminum foil, and it is fairly
heavy and bulky.

Paper packages are primarily used for bandages, gauze,

or other types of products which are not affected by atmospheric
constituents.
Plastics provide the most versatile type of packaging materials
as they possess most of the suitable properties mentioned above (65,79-

84). The major disadvantages of plastics are permeation, leaching,
...

sorption, chemical reactivity, and alteration of structure (79-82,

93).

84-

Permeation refers to the passage of gases, microorganisms, drug

constituents, and air constituents through the package.
permeation can occur in either direction.

Obviously,

Similarity of chemical struc-

ture between the plastic and the permeant increases permeability as do
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elevated temperatures and increased atmospheric vapor pressure.
decr~ase

A

in plastic crystal] inity will also increase permeation.

lncreas-

ing the thickness of the plastic does not necessarily decrease permeation.
Effects of permeation are an increase in chemical degradation rates, pH
changes (due to carbon dioxide), changes in drug potency, and biochemical
degradation due to microbial contamination.

Leaching is defined as the

migration of an additive from the plastic into the drug product.

While

pure plastics can exhibit leaching of components, the compounded plastics
create the major problems.

Stabilizers are the most commonly leached

substances and cause most of the toxic reactions due to plastics.

The

pH of the drug product must be compatible with the plastic to minimize
leaching.
Sorption is defined as the migration of a component of a drug
product or the drug itself into

o~

onto the plastic.

It is a physical/

chemical process and usually involves amorphous zones.

Consequently,

polar plastics exhibit greater sorptive properties than nonpolar
plastics.

Low molecular weight and ionic or electrically charged drugs

have greater sorptive tendencies while steric and internally bonded
drugs are sorbed less.
drugs.

A decrease in pH increases sorption of acidic

If the plastic and solvent system are both polar or both non-

polar, increased sorption occurs because like systems cause swelling and
open up sorptive passages.

Increased drug concentrations and increased

temperatures also facilitate sorption.

It is the chemtcal structure of

the drug product and plastic which determines if sorption will occur;
all other factors only affect the magnitude of sorption.

If both

adsorption and absorption occur, the quantity adsorbed is insignificant
with respect to the quantity absorbed.

Some documented examples of
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drug-plastic sorption are those of nylon with some antimicrobials;
polyvinylchloride will sorb benzalkonium chloride while polyethylene
will sorb some steroids.

Low density polyethylenes have been noted to

sorb scopolamine, pilocarpine, ouabain, and other similar compounds (85).
Chemi6al reactivity between drug and plastic may result in
physical changes of the plastic such as discoloration or deterioration.
For example, benzyl alcohol, benzaldehyde, and paraldehyde will etch
and dissolve polystyrene; certain oils will dissolve polyethylene;
fluorinated hydrocarbons attack polyethylene, polystyrene, and polyvinylchloride.

The choice of the right plastic polymer will help avoid such

problems (85,87,89).
interactions.

Alteration is usually due to these four drug-plastic

For example, gases or vapors may cause swelling or

collapsing of the package depending on which way the gas permeates.
Heat, UV light, ethylene oxide, and other sterilization procedures may
also deteriorate some plastics (85,87,89).

""'=-

Provided no contraindications

with respect to these disadvantages are present, Estevez et al. (81)
state that plastics should be used when:
1.

Plastic offers particular functional advantages.

2.

The drug product is so expensive that breakage must
not occur.

3.

The drug product is so dangerous or obnoxious that
breakage must not occur.

4.

The risk of breakage is high and the con$equences of
broken glass are ~ery dangerous (e.g., in nurseries, etc.).

5.

Mailing and transportation costs are based on weight
and thus, are high.

6.

Use of printed containers is advantageous.

7.

Specific shapes are desired.

8.

Plastic is the only practical choice.

=

~
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Drug manufacturers must ascertain the potential of drug-plastic interactions as well as the stability aspects of the plastic itself (81).
While many authors have cited some specific drug-plastic interactions
(62,79,80,85,88-92,94-96), any time a new drug-plastic system is used,
~-

storage of the packaged drugs at various conditions and subsequent
analysis must be done (62,87).

Stability of drug products has already

been discussed.
To determine changes in the plastic, impact resistance, average
tensile strength, average ultimate elongation, melt Index, infra-red
analysis, and moisture permeability tests must be performed before as
If

well as after storage.

In addition to these tests, physical inspection

of the package with respect to rupture and/or swelling must be done to
determine stability.

~-

Toxicity due to plastics appears to have been overestimated (81,
86,90).

However, toxicity can occur directly from actual contact with

the plastic as well as indirectly via contents of the package.

The most

common acute toxic reaction caused by pure plastics is sensitivity;
however, it is rare.

Compounded plastics as used in catheters or other

internal devices, can cause thrombosis, embolism, thrombophlebitis, and
necrosis.

Also, if the plastic is contaminated, septicemia and

bacteriuria may occur.

In addition, such devices have been known to

break-off in the body and cause physical damage to the circulatory system,
urinary tract, etc.
in the plastics.

Direct toxicity is usually due to stabilizers present

Chronic toxicities are manifested chiefly by neoplasms.

While not yet seen in man, various malignancies in other animals have
been caused by plastics such as polyethylene, polyvinylchloride, nylon,
and others.

Various mechanisms have been suggested as to the
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carcinogenicity of plastics (90).

Indirect effects are usually due to

plastics used as occlusive dressings where excess percutaneous absorption
may occur.

Also, solutions and/or blood stored in plastics may leach

some of the harmful additives (90).
Metals are used mainly for packaging aerosols and nuclearpharmaceuticals.

In addition, laminated aluminum foil, because of its

impermeability and light weight, is the package of choice for moisture

gamma-radiation (83,84,98,99).

Laminates, such as lacquers, vinylchloride,

and polyethylene, are used to provide a heat seal.

Because polyethylene

adds mechanical support, it is the most widely used (100).

The seal

should be peelable so that sterile products can be removed aseptically.
Hughes (100) adds that the heat seal is the most common cause of
defective aluminum foil packages.

The sealing process must be tested by

immersion in water for five minutes and then inspecting the package
visually for moisture.

Hughes also states that laminated aluminum is

the most moisture impermeable flexible package.

To assure impermeability,

at least 0.018 mm and preferably 0.03 mm gauge foil should be used
{83,100).

Often the outside of the foil is coated with cellophane to

increase impermeability and add an aesthetic sheen to the package (101).
In general, laminated aluminum foil meets almost every suitable property
cited.
Sterilization
Sterilization is a process by which all microorganisms are kil Jed
or removed such that they are no longer detectable in standard culture
media in which they are known to grow {102,103).

Bowman (49) adds that

~-
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sterilization does not necessarily kill all microorganisms but rather

~=
t; ..

H-

reduces them in number such that they cannot multiply in favorable media
and thus, the sterilized article is made safe for use.

The common

sources of contamination are raw materials, equipment, containers, per~-

sonnel, environment, and the user (102).
There are numerous methods of sterilization.

Boucher (I 08)

defines disinfection as a method which destroys disease causing microorganisms; only when it becomes powerful enough to kill all types of
microorganisms, is it a sterilizing method.

The AOAC test established

by the USDA is used to determine if a disinfectant is, in fact, a
sterilant.
The various sterilizing methods possess specific advantages and
disadvantages with respect to usefulness.

The properties of the articles

to be sterilized and the properties of the sterilant will determine what
method is best (102).
methods.

Some generalities apply to all sterilization

These include testing, certification, and adequate record

keeping of sterilization cycles.

In addition, quality control must be

employed using suitable indicators and testing media as well as strict
(

adherence to procedural and operational instructions.

The proper train-

ing of personnel is imperative (103,105,109,110).
Autoclaving is an easy and effective sterilization method withe
toxicity or residues.

It is easily_ controlled and measured and is

economical after initial installment.
be sterilized with this method.

A large majority of articles can

However, oils, greases, powders, and

similar substances cannot be penetrated by steam and sharp instruments
are du 11 ed.

A11 air must be removed from the chamber and some drugs are

deteriorated by high temperatures and steam.

The mechanism of action is

~-
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enzyme inactivation and protein denaturation.

In general, autoclaving

is the best method of sterilization when it can be used (103,108).
A dry heat oven with air circulation becomes a very'useful method
of sterilization.

Temperatures of 160°- 170° for 1-3 hours will kill

most microorganisms and destroy pyrogens (103).

Again, enzyme inactiva-

tion and protein denaturation are the mechanisms of action.

The major

advantages of dry heat are that instruments are not blunted or corroded,
11-----~am.:J~o-r--1-g-;---powders,

and steam sensiTive drugs can be sterilized.

Its

disadvantages are long exposure times and high temperatures (103).
While not practical for hospitals or laboratory use, irradiation
with

x~

or gamma rays is a very effective means of sterilization (98,99,

103,108,111).

Sterilization occurs directly via ionization and

indirectly via diffusion of radicals (108,111).

Gram negative bacteria

are very sensitive to radiation while viruses, yeasts, fungi, and spores
exhibit varying degrees of resistance.

Major sources of these steril-

izing rays are Co-60 and Cs-137 (99,108).

The advantages of irradiation

sterilization include quality control as to number and energy of the
radiations; the products do not become radioactive; it is effective
against most microorganisms; and it penetrates most packaging materials.
Its disadvantages are that trained personnel are required and some
packages are destroyed.

Factors affecting radiation sterilization are

presence of oxygen or other protective compounds, physical state and
water content of the microorganisms, and temperature (108).

B.

pumilu~

and B. stearothermophilus are the recommended biological indicators
(104,108,109,111).

Radiation is the best method to sterilize topical

drug products, especially enzyme preparations, and is the best method to
sterilize laminated aluminum foil packages as mentioned earlier.

Dietz
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(99) has reviewed the aspects of contract sterflization and discussed the

many advantages it possesses, including relative inexpensiveness.

It is

best to sterilize the finished, packaged product (98,99).
Ultraviolet radiation photons of high energy kill microorganisms
via DNA inhibition (112).

Maximum bactericidal effects occur at 240 to

280 nm; 253.7 nm is used commercially because most UV lamps emit 95% of
radiation in this

latte~

wavelength (108,112).

Applications are limited

th_a_t-ti\i--rays have poor peneiTarl ng power and-1:hus, can on lyoe used
on clean surfaces with simple geometry and at short distances (108).
Also, certain plastics polymerize on exposure to UV rays (108,112).

Its

major use is in the sterilization of room air for which it is highly
effective (113-116).
Fl ltration employs the use of screen filters which have a pore

size of 0.22 microns or less (117).
synthetic polymers, or silver films.

These filters are made of cellulose,
The pore volume constitutes approxi-

mately 70-85% of the filter diameter so that high flow rates are achieved

(118).

The filters are inert, maintain their original integrity, do not

impart fibers or debris, possess minimum adsorption, and are resistant
to water, dilute acids, and hydrocarbon solvents.

They do not affect

the pH of filtered solutions and are very useful for sterilizing drug
products which are sensitive to· heat or cannot be sterilized by other
methods.

Disadvantages are that the filters are not resistant to

corrosives such as nitric acid, sulfuric acid, sulfur, and cyanide so1ution.

Silver membranes undergo the usual silver reduction reactions

(118).
Ethylene oxide {EtO) gas was first used as sterilizing agent in

1933 (119).

Because of its high solubility, it penetrates most porous

;;;-

materials (103,108,120-122).

When conditions are appropriate, EtO kills
L~

g_

all microoorganisms via alkylation of sulfhydryl) amino, hydroxyl,
carbonyl, and phenolic

gro~ps

ii
s---

present in the organism (108,121,123-127).

This alkylation, shown below, causes irreversible metabolic changes in
~-

the organism.

HH
H 2 c~cH 2

+

protein-SH

~'=~~'1~

protein-S-C-C-OH

~~~~'~-~~~~~~~~~~HH~~~~EtO

viable organism

killed organism

Dessicated occluded spores provide protection from EtC's lethal effects

(112, 124); however, if articles are cleansed of debris, usually the
occlusivity is interrupted and the organism becomes susceptible (125).
Sykes (1 12) stated that the two most resistant bacteria to ethylene
oxide are

Staphyloc~ccus

and B. anthroides and yet, at a concentration

6-7 hours, these organisms were killed.

of 500- 750 mg/L of EtO for

Because EtO is explosive, it is usually diluted with carbon dioxide,
nitrogen, or Freon 11 or 12

(103~108,112,122,128).

These diluted mix-

tures require longer exposure times than pure EtO (128).
of an EtO sterilization cycle vary with dilutions.

The conditions

While different

conditions have been used successfully, all investigators state that
certain procedures will afford greatest efficiency (103,105,108,112,120-

124,128,129).

Elevated temperatures, i.e., 50°, relative humidity of

30-80%, exposure times of

!1-12

to 1000 mg/L are recommended.

hours, and EtO concentrations of 450 mg/L
In addition, an aeration time of 100 hours

at room temperature or 8-12 hours at 50° should be used.

\

Further, vacuum

for undiluted EtO and positive pressure for diluted EtO are recommended.

i; __
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The main advantages of EtO are that it is effective against all
microorganisms; the procedure is simple and causes little damage to
articles.

Further, it is useful for products sensitive to excess heat

or_steam; it penetrates most packages and is relatively inexpensive.
Its disadvantages include explosiveness, long exposure and aeration tlmes
as well as toxicity.

Direct toxic effects of EtO, its residues, and its

two commonest derivatives, ethylene glycol (EG) and chlorohydrin (EC)
have received much attention and some disagreement occurs among
researchers (103,108,112,120,127,130-137).

The general chemical

reactions forming these derivatives are shown below (108,127).
+

EtO

H

2

ce~CH

1
HO

EG

~later

+

2

IOH.

HCl

EC

EtO

These derivatives, like EtO itself, wi 11 dissipate from the article when
allovJed to aerate.

Aeration time is dependent on the type of package

being sterilized (103,108,112,120-122,128,138).

The greater the so1u-

bility of EtO in the package, the faster the steri1 ization, but also the
longer the aeration time

req~ircd

(120-122,134).

To determine residual

levels of EtO and its derivatives, many methods have been used (119,132,

- -; -- _:--~
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134,137,138).

Kaye (139) emphasizes that because of these toxic residues,

overtreatment for "safety margin 11 purposes must not be used with EtO

~-.;j

=

sterilization.
Boucher (108) has discussed various ~iscel laneous methods of

~-

sterilization.

Included in his discussion are the·use of B-propiolactone,

alkylanized glutaraldehyde, acid glutaraldehyde, iodine, formaldehyde
and others.

All have specific applications but because of various dis-

ad'ITCffftages, they are not commonly used to sterilize pharmaceuticals.
Once a method of sterilization has been chosen, both indicators
and sterility testing must be employed.

Bruch (107) has stated that

two basic types of indicators are available, biological and chemical/
physical.

He claims that biological indicators are the only indicators

which can evaluate or integrate all sterilization parameters and that
they provide the best assurance of sterility.

Commonly used organisms

as biological indicators are B. subtilis var. niger for wet and dry heat
(104);

!:.~milus

and B.

stearothermophilu~

for gamma irradiation (lah,

108,109); and~.. stearothermophilus for EtO (104,105,109,140).
B. stearothermophilus is one of the commonest biological indicaters available commercially (109,140).

Brewer and Arnsberger (140)

have developed a method which combines a chemical indicator and the
biological indicator, B. stearothennophilus.

The chemical indicator,

4-(4-nitrobenzyl·) pyridine, forms a blue color when exposed to EtO .
.....

Thus, 4-(4-nitrobenzyl) pryidine will indicate if EtO has permeated the
package and B. stearothermophilus will indicate if the concentration was
sufficient to sterilize the article.

The chemical reaction for

4-(4-nitrobenzyl) pyridine and EtO is shown below.
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-OH
+

~1-:.t·~~ ....·,~'f'~~.....\~

,,

..

4- ( 4-n it robenzy,~l'_/)._______..E._,t~O_________~S_t_ab_l_e_cbmmogens._ _ _ _ _ _~_
pyridine

Sterility testing involves culturing samples of each lot in
suitable media.

Either direct inoculation of the sample into the media

or solubilizing the product, filtering it, and then culturing the filter
may te used (102,104).

The main purpose of testing is to create optimum

conditions for microbial growth; thus, suitable media must be employed.
The USP XVI I (141) recommends Fluid Thioglycollate Medium (FTM) and
Sabouraud 1 s Media.

However, Soybean Casein Digest (SCD) has replaced

Sabouraud 1 s Media in the USP XVIII (106).

Sterility testing is not an

absolute guarantee since cultivation of all viable microoorganisms is
impossible, sampling is many times inadequate, and failures in technique
may occur (104).

If a product contains an antimicrobial or preservative,

it must be inactivated prior to testing (142).
th~

appropriateness of seven test media.

Abdou (143) has compared

His results showed that

peptone liver digest broth, peptone 1 iver digest agar, and dithionitethioglycollate media were superior with respect to cultivating all types
of microorganisms.

If more concurring data is accumulated, these media

may v.Jell replace the more common ones.

All regulations regarding

sterility testing allow for accidental contamination (104).
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When performing sterility tests and using biological indicators,
both positive ahd negative controls should be used (142) and one must
always recognize that none of these methods are an absolute guarantee
that the entire load is sterilized (102,105,107,110,121,124,128).
Review of Objectives
A water soluble, flexible dry foam was developed for application
to denuded skin areas (l-3).

The foam demonstrated therapeutic eq-"<u-'-iv.,_.a..._-_ _ _ _ __

lence when compared to commonly used ointment bases.

Hm"Jever, the foam

was physically unstable as deterioration and/or loss of flexibility
occurred after storage at various conditions.
This study will improve the stability of the dry foam by modifying
the original formula, determining a suitable packaging material, and
defining optimum storage

conditi~ns.

Medicated dry foams using nitro-

furazone and sliver sulfadiazine~ill be prepared, packaged, and stored
at various conditions; in vitro release will be compared before and after
storage to determine stability with respect to shelf-life.

In addition,

the foam will be rendered sterile since it is best to use sterile
products on open wounds.

CHAPTER II
EXPERIMENTAL
All chemicals and materials and all equipment used in the
experimental procedures are 1 isted in Tables I and I I respectively.
Preliminary Studies
At the onset, it was assumed that the original formulation (1)
could be satisfactorily packaged in plastic bags.

Thus, the following

formula was manufactured:
Dextran

'16. 00 g

Sorbitol

10.40 9

Miranol

0.20 g

Water

;::::;-

76.00 g

The dextran was added to the water and heated on a water bath to 70°.
The sorbitol solution was then added and the solution poured into a bowl
containing the Miranol.

Using an electric kitchen mixer, the solution

was whipped for ten minutes producing a light, white foam.

The foam was

then spread onto four Teflon coated metal sheets, each fitted with two
12 11 x 1-1/2 11 x 1/1611 plexiglas strips for control of uniform spreading.
Prior to spreading the foam, a light coat of silicone was applied to the
sheets to aid in removal of the final dry foam.

The pans were then

placed in a horizontal laminar flow hood with an air velocity of
110 ft/mln. and turned every fifteen minutes.

After one hour of drying,

the dry foam could be easily removed from the pans with a rubber spatula.
An oven set at 40-45° would allow faster drying, but because temperatures

TABLE I
Ch~~icals

and Materials Used in the

I

I

Na.~e

I

.I

I

r

i

Lot No. or Other
... Identifying .Xarks ....
34C-1350

Sorbo Solution, 70%

606K6

Glycerin

9209t172ST
3022002

Silicone, D.C. 556

6

Nitrofurazone Powder

aJ~turer
~-~

Sigroa Corporation, St.ILouis, l1o.
The Ruger Chemical Co.!, Irvington, N.J.
The

~1iranol Co., IrvinJ~ton,

N.J.·

Colgate-Palmolive Co., INew York, N.Y.
The Ruger Chemical Co.d Irvington, N.J.

Eaton Loboratoriea, Notioh, N.Y.

Nitrofurazone Cream, 0.2%

708900

Eaton Laboratories, Norlwich, N.Y.

Silver

7115 BS

Harion Laboratories, Kansas City, Mo.

Silver Sulfadiazine Cream, i%

E4547

Marion Laboratories, Kjnsas City, Mo.

Unibase Cream

PK 310

Sulfadiazin~

Powder

Drierite

Ethylene Oxide, 100%
B. subtilis spores
Ethylene Oxide Indicator
Staphylococcus aureus

I

Man uf

E96n9

Calcium Chloride

l

Ij

FJ:>ocedurer

I

Dextran, M.W. 73,200

l1iranol 2MCA Modified

ExperL~ental

1-l.A.

3M Co., St. Paul, Minn.

Attest

3M Co., St. Paul, Minn.

Index

3M Co., St. Paul, Minn.
A~erican

I

Type Culture Ciollection, Rockville, Md.

Antibiotic Medium 2

525075

Difco Laboratories, Det:!:'oit, Mich.

Fluid Thioglycollate Medium

575191

Difco Laboratories, Detj::>oit, Mich.

Soybean Casein Digest Hedium

614363

Difco Laboratories, Dettoit, Hich.
.

I

~~m~' "iiT'illil 'Y
I

"

I·

Hammond Drierite Co., Xenia, Ohio

EPA #7128-1

A.T.C.C. #25293

I

P~ko-Davia Co., Det~+· Mich.

I
I!

I

I

I

JJL"I
I

I:: IJ:llffl"~['

\N

0

I,

! l!ll. .: :r::

llj

I

I

TABLE II
Equipment Used in the ExperL~antal Procedures

I

I.

Equipment

II

Seal-A-Heal Bags

j

Heat Sealer

I

Cenco Moisture Balance

/

I

I ~=~nated ~~ne®

J

I

1

.uaiT.lnated AJ.UmJ..nurn Fo1.l oags

I

Fisher-Lilly Zona Reader

I

I

Foil :ags

l

I
_::nufacture,,
Dazey Corporation, KanJas City, Mo.
Dazey Corporation, Kanslas City, Mo.
Central Scientific Co.

,I

Chicago, Ill.

Eli Lilly Co. , Indianap:olis, Ind.

The Rexham Corporation,! Charlotte, N.C.
Fisher Scientific Co., :!?ittsburgh, Pa.

Ethylene Oxide Chamber, Model 200

3M

Co., St. Paul, Minn.

I

Ethylene Oxide Aeration Chamber, Model 33

3i'! Co., St. Paul, Minn.

I

Airguide.
#605 Relative Hu~idity Indicator
,

Ail,~'f...!ide I~s"trt:rr;en't Co.

i, Chicago, 111.

I

Springfield #552 Relative Humidity Indicator

Springfield Instrument

J~o. ,

Hackensack, N.J.

I

I

w

!

1~mr111~'

"iir'IIIII'F

1
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in an oven are not uniform, uneven drying would occur causing the foam
to be too dry in some areas and still be wet in others.
app~oximately

50 x 30

~n

Small strips

were cut, weighed on an analytical balance,

packaged in Seal-A-Meal Bags, and heat sealed.

The packaged samples were

then stored in a refrigerator (5°; R.H., 55·60%), a freezer (-5°; R.H.,
75-90%), and at room conditions (22°; R.H., 40-50%).

On the day of man-

ufacture, moisture content was determined by weighing six samples on the
{\-------.an-a-1-yth:<rl-b-cd-alTc-e-;-0-.yirrg-fhem to constant weight at n 1 nety vo 1ts on
the Cenco Moisture Balance, and then calculating moisture content
according to the loss in weight.
was due only to water loss.

It was assumed that any loss in weight

Average moisture content on the day of

manufacture was found to be 12.7%.

Four samples were removed and

analyzed for moisture content after one, two, three, four, six, eight,
and twelve weeks of storage.
above procedure.

Table I I I summarizes the results of the

The changes in moisture content indicated that the

plastic bags were permeable to moisture and showed that changes in
relative humidity could cause the dry foam either to lose or to gain
moisture.

Maintaining approximately a 10% moisture content is advisable

to yield a flexible, nonsticky product (1).

That is, a significant loss

of moisture causes the foam to lose flexibility while a significant gain
causes the foam to become so moist that it adheres to the package or
dissolves when touched.

The data in Table I II

indi~ate

the variability

~

of moisture contents of the dry foam packaged in plastic.

These changes

not only show that plastic alone is not a suitable package, but also
confirms the necessity for a moisture impermeable package.

Further, the

data indicate the need to establish optimum storage conditions with
respect to. temperature and humidity.

~-

TABLE III

Average Per Cent Moisture Content* of Unmedicated Dry Foam in PlasTic Bags
Duration of
Storage

Room Conditions
(22°; R.H., 40-50%)

§efrigerato::::(+5 ; R.H., 55-60%)

1 week

12.6

14.2

16.2

2 weeks

13.9

14.6

17.6

3 weeks

14.0

14.5

Deteriorated

4 weeks

12.6

13.2

Deteriorated

6 weeks

13.4

12.8

Deteriorated

8 weeks

11.3

12.2

Deteriorated

12 weeks

12.7

16.0

Deteriorated

13.0

16.3

MEAN

I

0 Freezer
(-5 ; R.H., 75-90%)

16.9

*Average moisture content of 6 samples on day of preparation was 12.7%
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Acceptability of a packaging material, based on changes of moisture content in percent, was arbitrarily set as below.
1.

2.

3.

4.

Excellent:
Good:
Fair:
Poor:

< 0.5%
< 1.0%
< 2.0%
> 2.0%

change;
acceptable
but > 0.5% change; poss. acceptable
but > T.O% change; not acceptable
change;
not acceptable

Lining the plastic bags with waxed and parchment papers, as well
l------'as_tJsJ_n_g_d_o_u.b-1-e-p-1-a--S-t=-i-e-b-a-s-s~,-d-i-d~R-e-t-i-n-l\3-F-0-V-e---:-J3~1-y-s-i-e-a-1-s-t-a-b-i-1-i-t-y-e-f-t-h-e------_

foam (see Table IV).

Rather than search for a moisture impermeable

plastic, it was decided to seek alternate packaging materials.

Carre-

spondence with a number of packaging manufacturers and users suggested
that laminated aluminum foil bags would meet the moisture impermeable
requirements most satisfactorily.

It was also decided to modify the

formula in an attempt to decrease moisture loss by adjusting humectant
content.
Laminated aluminum foil bags were secured from Eli Lilly and Co.
These bags had a 0.00075 inch thick aluminum foil sandwiched between an
outer coat of eel lophane and an inner coat of high density polyethylene.
As implied earlier, ideally, the dry foam should be flexible,
easy to handle, i.e., does not stick to package or to hands, and be
soluble on moist· skin.

These parameters apply at the day of manufacture

as wel 1 as after storage at various temperatures and humidities.
lesser but nevertheless significant criterion is the pore size.

A
The dry

foam is a very porous formulation and any changes in pore size after
storage would indicate deterioration of physical structure.
Nitrofurazone 1% and silver sulfadiazine 1% dry foams were prepared using three different concentrations of glycerin in addition to

~-
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TABLE IV

Average Per Cent Moisture Content of Unmedicated Dry Foam

:

in Plastic Bags with Liners

r

Duration of
Storage

Room Conditions
A

A

Refrigerator

(22°; R.H., 40-50%)
B.

(+5°; R.H., 55-60%)

C
'

0 Freezer
I
(-5 ; R.H., 75-lO%)

0

Oven

(37 ; R.H., 25%)

A

B

C

A

B

d

A

B

C

8.5%

8.1%

8.9%

9.3%

8.0%

9.4%

4.4%

4.3%

4.7%

10.6% · 8.9% · 10.5%

3.1%

3.3%

3.3%

1 week

6.4%

6.7%

7.1%

2 weeks

6.3%

6.0%

6.3%

9.0%

8.6%

9.3%

3 weeks

7.5%

7.3%

7.3%

9.2%

9.1%

. 9.2%

12.6%

10.5%

11.r%

5.2%

5.2%

5.3%

4 •• ~.

6,61

6.4%

6.71

9.6.

9.2.

9.41

15.31

12 .••

13.rl

3.91

3.91

3.9%

MEAN

6.7%

6.7%

6.9%

9.1%

8.8%

9.2%-'-~2.0%

10.1%

~~·I'

4.2%

4.2%

4.3%

= bags

'

lined with waxed paper; average moisture content of 12 samples on day of prepi3.I'ation

I
I

.

= 9. 3%

· B = bags lined with parchment paper; ave. moisture content of 12 sampies on day of pre!)aration = 9. 0%
C = double bagged; average moisture content of 12 samples on day of preparation =

I

10.1~~
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sorbitol.

Also, the original formula without glycerin was manufactured

for comparison.

Moisture content and subjective evaluation of gross

physical properties, i.e., flexibility, stickiness, dissolution time,
porosity, were determined on the day of manufacture.

Samples of each
~-

dry foam were then weighed, packaged in the foil bags, and heat sealed.
Three samples were stored for one week at the following conditions:

The various formulas for nitrofurazone dry foams are listed in Table V
and for silver sulfadiazine, Table VI.

Table VI I lists the moisture

content and subjective evaluation of the nitrofurazone formulas on the
day of manufacture and after storage.

Table VI II

su~1arizes

these data

for silver sulfadiazine foam.
Because these formulas (see Tables V and VI) were too sticky,
three additional formulas with decreased concentrations of glycerin were
prepared and compared to the original.

Additional storage conditions of

room temperature, refrigerator, .. and a laboratory oven were included in
the stability studies.

Because laminated aluminum foil bags maintained

satisfactory moisture content (see Table VII and VIII), moisture content
-

determination was not done in this part of the study.

The additional

fonnulas are listed in Table IX for nitrofurazone and Table X for silver
sulfadiazine.

The subjective evaluations are summarized in Tables XI

and XI I respectively.
These preliminary tests indicated that modification of the
original formula with glycerin in concentrations greater than 0.19% wet
weight, i.e., formulas II-VI of nitrofurazone and silver sulfadiazine,

~
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TABLE V
Composition of Original (I) and Modified Formulas (II-IV) of 1% Nitrofurazone! Dry Foam
I

MiraAol

Glycerin

Nitrofurazone

Water

Dextran

Sorbitol

28.5*

6.0

3.9

II

27.6

6.0

3.9

0.94.

III

27.8

6.0

3,;9

0.75

o. 0715

0.11

IV

28.1

6.0'

3.9

0.38

o. 0715

0.11

Formula Number
I

* Quantities

\'

o.or
o.or
I

0.10.
0.11.

are listed in grams.

TABLE VI
Composition of Original (I) and Modified Formulas (II-IV) of 1% Silver Sulfadii3.zine Dry Foam
,

.

I

Water

Dextran

Sorbitol

28.5*

6.0

3.9

II

27.6

6.0

3.9

III

27.8

6.0

28.1

6.0

Formula Number
I

~

Glycerin

IV
. .

.

* Quanti~ies

are l:i,sted, in

I

I

Miran~>l
I

Ag Sulfadiazine

o. 0751

0.10

0.94

o. 07~1

0.11

3.9

0.75

0.071

0.11 .

3.9

0.38

0.07S

0.11

\

... . . .

.

..... I·

w
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grams~
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TABLE VII
Average Per Cent Moisture Content and Gross Physical Appear.:'fce (GPA)
of Nitrofurazone Formulas in Foil Bags* Before and After Sforage
Formula
No.
I

c

B

A

10.8%

10.0%

10.2%

II

9.8%

9.8%

10.1%

III

9.1%

8.9%

9.3%

GPA on Day of
Preparation

GPA in Freezer
(-!f; R.H. 75-90%)

Flexible
Dissolved on moist
skin in 15 sec.
Not sticky
Even porosity

Unchanged

Very flexible
Dissolved on moist
skin in 15 sec.
Sticky
Even porosity

Increased
porosity
Other properties
unchanged

Same as II

Same as II·

II

IV

9.0%

9.3%

9.4%

Less sticky than
II and III
Other properties
same as II & III

G~A

I

Stuck to bags
Slight loss of
flexibility
Other propercies
unchanged

I

I
I

in Dessicacor

(2f>; R.H. S-6%)

I

Great increase in
porosity
Stuck to bags
Other properties
unchanged
Same as II
I

Slightly stuck to
bags
Slight loss of
flexibility
Other properties
unc:hanged

Unchanged

I

w

6o

,m~.~''"m'iil'r~

'I

[.:
I

I

1.•;•1·

... II ..'·

"I
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TABLE VIII
Average Per Cent Moisture Content and Gross Physical Appearlmce (GPA)
of Silver Sulfadiazine. Formulas·· in Foil··Bags 1'•··Before--and··Afi:er Storage
Formula
No.

I

A

c

B
I

10.9% I

I

9. 4%

GPAon Day of .
. Preparation ...

I

Flexible
Dissolved on moist
skin in 15 sec.
Not sticky:
Even porosity

GPA in Freezer

'

..(-5°; R.H. 75-90%)

Unchanged

~;

GPA in Dessicator

1

'
r1

!
j'

.. I... ...
II

)II

IV

..

J.

10.5%

10.4%

9.7%

Very flexible
Dissolved on moist
skin in 15 sec.
Sticky
Even porosity.

Increased
porosity
Increased
stickiness
Other pr·operties
.. unchanged .

9.3%

9.0%

9.1%

SaJne as II

Same as II

8.8%

8.8%

8.7%

Less sticky than
II and III
Other properties
same as II & III

tJnchariged

.(22°; R.H. 5-6%)

Slightly stuck to
bags
Increased porosity
Slight loss of
flexibility
Other properties
uncha;::.ged
Great increase in
porosity
Stuck to bags
Loss of flexibility
Other properties
unchanged

II

Same as II
Same as I in dess.
except ·still sticky·

lr

*Eli Lilly and Co., Indianapolis, Indiana
·W
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TABLE IX

Composition of Original (I) and Additional Formulas (V-VII) of 1% Nitrofurazone Dry Foam
Water

Dextran

Sorbitol

I

28. 5)'<

6.0

3.9

v

28.2

6.0

3.9

VI

28.4

6.0

3.9

Formula Number

VII

28.4

3.9

6.0

Glycerin

Mtcl

Nitrofurazone

o.r75

0.10

0.30

o.r75

0.10

0.15

0.075

0.10

0.075

-

I

0.075

',

i

0.10

I

* Quantities are listed in grams

TABLE X

Composition of Original (I) and Additional Formulas (V-VII) of 1% Silver Sulf,diazh:e Dry Foam
• I •
MJ..r,no.l.

Ag Sulfadiazine

0. 0175

0.10

0.30

o. 0175

0.10

3.9

0.15

o. 0175

0.10

3.9

0.075

o.or5

0.10

Water

Dextran

I

28.5*

6.0

3.9

v

28.2

6.0

3.9

VI

28.4

6.0

VII

28.4

6.0

Formula Ntunber

* Quantities

Sorbitol

Glycerin

are listed in grams
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TABLE XI
Gross Physical Appearance (GPA) of Additional
Nitrofurazone Formulas Before and After Storage'
Formula
No.

I

Gross Physical Appearance After ~Storage in

GPA on Day of
Preparation
Freezer

Refrigerator

(-'5°; R.H. 75-90%)

(+5°; R.H. 55-60%)

(22 °; R.H. 5-6%)

Dessicator

Flexible
Dissolved on moist
skin in 15 sec.
Not sticky
Even porosity

Increased porosity
Other properties
unchanged

Unchanged

Loss of

Flexible
Dissolved on moist
skin in 15 sec.
Less sticky than
II-IV
Even porosity

Increased
stickiness
Slight increase
in porosity
Other properties
unchanged

Same as V in
freezer

Very flexible
Dissolved on moist
skin in 15 sec.
Less sticky than
II-V
Even porosity

Unchanged

tin changed

Room

Oven
(37°; R.H. 25%)

(22°; R.H. 45!',,)

I

I

v

I

II

VI

VII

I

Totally
deteriorated

flex~bility

Same as V in
dessicator

Same as I in
dessicator
J

Other properties
unchanged
Loss of
flexibility
Great increase
in porosi-ty
Stuck to bags
Other properties
unchanged

I

I
Totally
deteriorated

S2,me as V in
dessicator

Totally
deteriorated

Sarr.e as V at

i

I

i

I
I

room

I
I

I
!

Very flexible
j Unchanged
Dissolved on moist
skin in 15 sec.
Not sticky
.
1
Even porosity

Unchanged

I

,r:wm~~r

"1~11111'1

Very slight loss
of flexibility
Other properties
unchanged

I

Totally
deteriorated

Same as VII
in dessic.

[
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TABLE XII

~

Gross Physical

Appeara~ce

~

(GPA) of Additional Silver

1

i

I!

Sulfadiazine Formulas Before and After Storage

u

,,~
lj

GPA oilDay of
Preparation

Formula
No.

Refrigerator

Freezer

(-5o; R.H. 75-90%)

I.
I

I

.

V

Flexible
Dissolved on moist
skin in 15 sec.
t sticky
en porosity

1

~
.

•
I
l
II

VI

I

I
I

VII

I
I

(+So; R.H. 55-60%)

·I

~~age~

Gross-P:tlysicar Appearance After

I

.

I

Dessicator
(220; R.H. 5-6%)

Oven
(370; R.H.25%)i

Slight loss of
flexibility
Other properties
unchanged

Totally
deteriorated

"
'!

t

Roor.1
(220;R.H. 45%) 1
I

Unchanged

Very flexible
Dissolved on moist
skin in 15 sec.
Less sticky than
II-IV
Even porosity

Unchanged

Very flexible
Dissolved on moist
skin in 15 sec.
Less sticky than
II-V
Even porosity

Unchanged

v:ry flexible .
Dlssolfed on molst
skin in 15 sec.
Not sticky

Unchanged

Unchanged

I

Unchanged

Loss of
flexibility
Great increase
in porosity
Other properties
unchanged

Unchanged

Same as V in
dessicator

1
Totally
deteriorated
.

l
j

II
I

To'tally
deteriorated

I

Unchanged

!
II

I
I

Unchanged

I

1

•

!I

I

j

1

...
Sa:ne as V in
dessicator·

~

'

.

I

I Sa:ne as I in
dessicator

Unchanged

1

I

.I!

Totally
deteriorated

!

1

•

1
I

Even porosity

j
Unchanged

I
!

I

I

I
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caused the dry foam to be too sticky such that it could not be easily
handled.

In a concentration of 0.19%, i.e., formula VII, the dry foam

was very similar to the original, but because it was felt that glycerin
would decrease the tendency to Jose moisture and thus, increase the
chances of maintaining flexibility, formula VI I was chosen for further
eva 1ua t ion .

From these preliminary tests, a three month storage study was

dry foams packaged in foil laminates and stored in a freezer, refrigerator, dessicator, and at room temperature.

Storage at elevated

temperatures much greater than room temperature were not satisfactory,
regardless of the package or the formula.

Also, the preliminary studies

indicated that laminated aluminum foil bags fulfilled the moisture
impermeable requirements (see Tables XI and XI 1).

However~

because of

the unavailability of the original foil bags, another type had to be
obtained.

This change was not considered significant since all laminated

aluminum foils are considered impermeable to moisture.

Thus, different

laminated aluminum foil bags were secured from the Rexham Corporation;
these new bags, starting from the inner side, consisted of a paper/
primer/polyethylene/.001 11 aluminum foil/vinyl wash/resin coating.
Procedure for Nitrofurazone 1%

Dr~~

The following formula was prepared:
Dextran

16.00 g

Sorbitol

10.40 g

Glycerin

0.20 9

Mi ranol

0.20 g

~-
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Nitrofurazone
Water

0.27 9
75.80 9

The identical procedures previously described for manufacturing, moisture
content determination, and packaging were followed.

Calculations for

determining the amount of active ingredient needed were done on a dry
weight basis using 10% as the average moisture content.

~=

The average

moisture content of ten samples on the day of manufacture was found to

A drug product must be both physically and therapeutically
stable.

Moisture content mainly affects the physical properties of the

dry foam; to determine if storage conditions, packaging material, and/or
time affected the therapeutic efficacy, in vitro release using a modified
agar plate method was done.

Antibiotic Medium 2 was made according to

the manufacturer's directions, autoclaved at 15 psi and 121° for 30
minutes.

Twenty-five ml were then poured into 15 x 100 mm disposable
~-

petri dishes.

The agar was allowed to gel and ten plates were seeded

with 0.1 ml of an overnight inoculum of _Staphyl_ococcus aureus A.T.C.C.
#25293.

Two sterile penicylinders were placed on the gelled agar plates;

one was filled with approximately 0.3 g of Furacin Cream 0.2% and the
other, with Unibase to serve as a control.

One disc of the freshly made

dry nitrofurazone foam was placed on each of the ten plates.

The plates

were incubated at 37° for 24 hours following which ~he zones of inhibition were read, using the Fisher-Lilly Zone Reader.
At monthly intervals, for a period of three months, four samples
of the dry foam were removed from each storage condition and moisture
content determined.

Also, one sample from each condition was removed

and in vitro release was determined using the above procedure.

45

Preliminary work with nitrofurazone indicated that 0.2% nitro6;--

furazone dry foam did not give equal or greater zones of inhibition than
the commercial cream.

Prob~bly,

this was not because the foam did not

release the drug, but simply because there was much less nitrofurazone,
i.e., subtherapeutic concentrations, per disc of foam than in 0.3 g of
Furacin Cream.

Therefore, the concentration of nitrofurazone in the

foam had to be increased to provide therapeutic concentrations.

Table

XIII summar-izes the average zones of inhibition from ten readings
obtained with varying concentrations of nitrofurazone.

One percent was

selected as therapeutically equivalent to the commercial cream.
Results for nitrofurazone dry foam for moisture content and in
vitro release on the day of manufacture and at one month intervals of
storage are listed in Tables XIV and XV.

Each sample shown in the

tables was taken from its own foil bag.
Procedure for Silver Sulfadiazine 1% Dry Foam
The following formula was manufactured:
Dextran

16.00 g

Sorbitol

10.40 g

Glycerin

0.20 g

Hirano 1

0.20 g

Silver sulfadiazine

0.27 g.

Water

75.80 g

The identical procedure described for nitrofurazone dry foam was employed
for silver sulfadiazine with respect to preparation, moisture content
calculations, and determination of a suitable package and of proper
storage conditions .. Average moisture content of ten samples of silver

=
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TABLE XIII

Zones of Inhibition Obtained vdth
Various Concentrations of Nitrofurazone

r
Drug

Mean Diameter (rom)
(average of 10 readings)

Furacin Cream 0.2%
Nitrofurazone Foam 0.2%

12.1

not distinguishable

Nitrofurazone Foam 0.5%

.6.4

Nitrofurazone Foam 0.75%

10.9

Nitrofurazone Foam 1. 0%

12.9

Nitrofurazone Foam 2.0%

14.3

Nitrofurazone Foam 3.0%

19.7

o.o

Control~·:

* Unibase,

Parke-Davis Co., Detroit, Mich.

·-~···~·.,··· ~,.,.,.,.
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TABLE XIV
l1oisture Content (%) of 1% Nitrofurazone Dry Foam
on the Day of Preparation and After Storage

Sa.11ple
No.

I

Day of
Preparation

1

9.8

2

10.2

3

9.6

4

10.8

5

10.4

I

6
7

9.3
8.8

I

8

9.4.

9

10

8.8
9.8

ME&~

9.7

p~··

One Month's Storage

I

.,,o Months'

Sto~ge

l

Three Months' Storage

A

B

c

D

A

B

C

8.8

9.2

7.4

9.4

9.5

9.6

7. 7-,

8.41

8.7

9.7

9.0

10.8

9.7

9. 61
9.3

6.0

9.8

9.5

9.7

9.9

9.3

10.2

I

9.4

4.6

8.6

10.1

9.1

7.8

10.0

10.0

9.6

8.9

12.6

9.6

9. 51
10.3

7.5

I
II

9.6

9.4

7_.2

9.7

9.5

9.7

D

A

I

I

B

'
9. 31 9.0

7.0

9.1

c

t

9.6

I

I

I

I

I

I

D

l

!I

!'
I

I

I

9.5

9.4

9. 71

< .7
> .5

<.9

<.5,

7.1

> . 3 I<. oo1

>· 7

9. s

9.7

9.7

>. 9

>.9 J :>.5

i

1

8.4 · 1

sl 9.2 1 9.91 7.7
I I I
<. sl <. 2 < . 7 I<. 02
> . 7 > .1 > . 5 i>. 01
9.

I

<. 7 <·OS
>.02

i

I
II
I

I

!

I

A= 220; R.H., 47-51%
B =+5°; R.H., 55-60%
~
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,L

, 1

•

r

.
1

I

i.JI

:1

ll

TABLE XV
Diameters (rnm) of Zones of Inhibition of 0.2% Nitrofurazone Crei3.m and
1% Nitrofur=ne Dry Fo"' on the Day of Preparation and After sforage

Plate
No.

One Month

Day of
Preparation

Two Months

c

11I

c

Cr

Foam

Cr

1

?

11.9

9.4

11.2

10.7

10.0

10.1

9.3

11.7

10.71

12.6

9.6

9.8

2

9.0

9.5

8.6

9.6

11.3

12.9

' 9. 7

10.7

11.7

10.0

11.2

3

10.2

9.8

9.9

10.8

12.0

11.2

9.4

9.5

10.0

11.41
10.1

10.6

4

i 10~1

9.6

9.3

11.9

10.5

11.0

9.5

8.2

9.6

11.41

10.7

B

A

D

I

Cr

A

B

D

Cr

c

B

A

D

13.11

11.4

12.8

12.0

11.2

14.0

13.0

13.0

12.8

10.1

10.1

12.5

11.4

11.8

12.0

9.8

11.0

12.5

12.2

12.1

12.1
13.5

5

9.9

9.4

10.0

9.8

12.1

11.3

10.0

10.2

10.5

12,0

11.8

9.4

11.5

12.5

13.8

11.2

6

10.6

10.8

9.3

10.3

12.3

12.1

10.3

11.1

11.8

12.3

10.3

10.2

9.9

12.3

12.8

12.2

11.8 '

10.6

10.5

9.3

9.9

11.7

10.4

8.9

10.0

12.5

12.0

12.6

10.8

10.5

12.7

12.7

12.6

13.4

8

10.3

11.6

12.5

12.6

13.4

13.1

13.2

13.8

10.61

12.9

11.9

11.0

9.6

10.1

1:1.1

11.0

11.3

12.8

12.2

:11.6

10.2

12.7

11.5

12.81

14.0

9.7

10.5

9.9

12.5

13.0

10.6

~~:~II

10.5

9.5

12.71
9.9

12.3 . 11.9

9

10.6

14.1

12.51

13.11

12.1

10.5

13.0

12c2

12.5

12.6

?3

p3

p3

p3

7

I

9.4

I

11'1

11.6

MEAN

10.2

11.5
10.6
p1

I
I

II

:i

Three Months

< .5
>.3
--·

10.41

11.11

11.3

9.8

10.7

11.6

11.3

10.1

p3

p3

p3

p2

.2
> .1

< .3

< .5

~2 II >·

p3

.s
•3

<.9
7

< .05
.02

>

<

> .2

I

--

-~

A= 22°; R.H., 47-51%

P

B = +5°; R.H., 55-60%

P

C = -5?; R.H,~- 75-90%
D = 22~; R.f{.~ 5-6%

~

1
2

9.9

>.3

12.8

'

11.5

11.7

11.4

p3

p3

p3

p3

.2
.1

'> . 9

< .1
>.05

< .02 <

>

> .01

10.611

I

I
I>

p2

<-5
.3

(.001

<

.01
.001

>

I

< .001 < .001

I
I

t

I
I

- Student t; crea."'ll vs. foam on day of preparJ.tion
- Student t; cream vs. cream after storage

3 - Student t; foam ys. foam after storage

-t::-

c:>

,mNrn~r

irn~n

'

Uli
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sulfadiazine dry foam on the day of manufacture was found to be 9.8%.

In

vitro release was compared to the commercially available silver sulfadlazine 1% cream.
Results for silver sulfadiazine dry foam for moisture content
and in vitro release on the day of manufacture and at monthly intervals
of storage are listed in Tables XVI and XVI I.

As with nitrofurazone,

each sample shown in the tables for silver sulfadiazine was taken from
its own fori-bag.
Sterilization Procedures
t1ethod I:
Unmedicated casting solution, i.e., dextran, sorbitol, glycerin,
Miranol, and water, was inoculated with 0.2 ml of an overnight inoculum
of

~~~

and then autoc 1aved at 15 psi and 121 o for 20 minutes.

The resultant solution was placed in a sterile bowl in a laminar flow
hood and whipped with sterile beaters.

The whipped foam was ascep-

tically spread onto sterilized pans and allowed to dry in the hood.
t1ethod II :
Unmedicated casting solution inoculated with 0.2 ml of an overnight inoculum of S. aureus was filtered through a 0.22 micron
Mi 11 ipore fi Iter into a sterile bowl.

This was done in a laminar flow

hood using a 50 ml syringe.· The solution was whipped with sterile
beaters and aseptically spread onto sterile pans and allowed to dry in
the hood.
Hethod Ill:
Unmedicated casting solution was inoculated with 0.2 ml of an

-·

-

· -.. ~W'>""'""'-'!n'--"'-"''

'rABLE XVI

Moisture Content (%) of 19,; Silver· Sulfadiazine Dry Fo ·~
on the Day of Preparation and After Storage
Day of
Preparation

Sample
No.

.One Month's Storage
A

I

1

9.8

2
3

B

8.1

8.8

10.7

9.2

9.1

8.9

4

9.2

9.7

5

9.9

6

1LO

7

9.2

8

10.2

9

9.3

10

9.1

p:l<

D

9.5

8.8

10.2

9.5

8.5

8.4

10.0

9.8

9.9

11.3

9.1

I
I

I

I

I

A

c

B

D

A

B

c

D

9.0

9.6

9.4

5.8

9.3

10.7

9.4

10.3

8.5

9.4

9.5

8.6

9.9

9.9

9.3

9.5

9.8

9.1

10.3

9.7

9. ~r
9.B

9.2

10'.1
10.4

10.2

12.5>

I

9.5

10.2

I

9.8

Three Months' Storage

I

I

I

10.8

..,

9.9
I

I

I

9.0

<

I

..
~

9.3

<

.3

> .2

:> .05

10.1

9.1

<. 7 <
>.5

.5
";>.3

I

I

9.3

10.2

10.0

10. s,

<. 7

< .3

< .7

<

> .5

> .2

> .5

,.1

•Ll
>.1

,,

I

l

)

9.8

MEAN

c

-

Two Months' Storage

I

I

9.2

9.9

< .2
)'.1

<:.9

>· 7

9.4

<

8.7

.31 < .2

>.2\~·1

"' Student t calculations comparing mqisture content on day of preparation with m::)isture content after storage

I
I
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TABLE XVII
Diameters (mm) of Zones of Inhibition of 1% Silver Sulfadiazine

Cl~eam

and

1% Silver Sulfadiazine Dry Foam on i:he Day of Preparation and AfteJ Storage
I

Day of
Preparation

Plate
No.

c

c

Three Months

I

Foam

Cr

9.8

11.8

11.4

11.3

11.5

11.3

. 11.3

9.4

11.6

10.5

11.1

10.1

2

10.8

10.6

9.7

14.3

15.0

15.5

13.0

8.7

12.4

10.0

12.5

10.6

9.8

3

10.2

11.4

8.8

12.0

10.9

13.7

12.5

9.2

10.8

11.6

10.7

11.5

8.2

4

9.4

12.2

10.5

9.8

9.6

10.8.

11.1

9.5

10.4

10.7

10.4

10.9

9.7,10.1

9.3

10.4

11.6

12.2

12.2

8.8

10.4

11.8

10.3

11.8

9.3

13.5

13.8

9.2

11.0

9.1

11.0

10.5

9.1

9. 91
10.51

12.4
11.8

12.0

9.1

'lo.o

I

A

I

Two Months

Cr

1

B.

D

A

Cr

B

D

5

9.0

11.2

6

9.4

12.1

7

10.6

11.5

9.5,11.6
11.0
9. 7

11.6

8

10.0
8.2

10.7
8.3

10~2

9
10

10.9
11.6

11.2

11.7
10.0

13.0
12.4

11.3
13.1

9.3
8.9

10.8
13.6

10.4
12.1

1.0. 9
13.6

10.7
11.6

10.8

'10. 8

9.1

11.1

10.1

10.6

11.0

8.9

11.9

13.2

11.4

9.8

11.4

9.8

11.2

11.2

12.4

12.0

9.1

11.2

11.5

p

p

p

p

F

p

p

p

p

Mt:Ai''i

1

I

One Month

.

I

< .001
-

2

9.7 '

3

3 .

3

< .9 < .1 < .2
> .9 <> .7
. 5 > . 7 > .05 > .1
- - - ~--

--~

-

3

2

3

<

.05 <..7
).5

> .02

---

--

.9

;. .7
'-----~

A

10.9

9.5

c

B

D

12.4

10.1!

10.0

10.1

11.3
11.5

10.71
10.0

10.2

10.0

10.1

11.7

10.6

10;2

10.2

11.5
9. 7:
10.5

10.1

9.~

10.1

11.1

11:.61

10.4

i12.ol1o.o
10.41 9. 9

13.3
12.5

11.5
10.3

12.8
11.1

12.5

I
ill.
5

11.5

11.9

10.3

11.4

10.9

~~0.1! 10.1

11.4

10. s

p

p

3

<

Cr

'

.9

9.4

<

>

9.8
10.6

1

I_ 11. 2.

p

3

3

>

I

.2
.1

~-~

p

2

3

I,= ·
~--:t · L__
7
5

<.001

_

p3

l

1

10.7

p3

p3

<·'I<

> .s'I >.os. >:_.os
.1 I
___
J

I

0

A = 22 ; R.H., 47-51%

P1 - Student t; crea1n vs. foam on day of pre parat :Lon

B =+5°; R.H., 55-60%

P2 - Student t; cream vs. cream after storage
P 3 - Student t; foam vs. foam after.storage

C =-5°; R.H., 75-90%
D = 22°; R.H,, 5-6%

\J"l

',mm~~:: "i,IT111n '.

I

'll

L:IIn II.
I
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overnight inoculum of S. aureus and whipped in a bowl.

The whipped

foam was spread onto a pan and allowed to dry in a laminar flow hood.

~

w--

The dry foam was removed and placed in ethylene oxide permeable plastic
bags obtained from Tower Products, Inc.

The packaged foam was then

placed in a cold cycle (29°) ethylene oxide chamber and the cycle
allowed to run for three hours using 100% ethylene oxide.
!!...:._subtil~were

Spores of

used as the biological indicator while lndox Ethylene

Oxraerncn cator· served as the chemica 1 i nd i cat or.

Upon comp 1et ion of

the cycle, both indicators showed that ethylene oxide sterilization
requirements were met.

The packaged foam was then aerated for eight

hours at 63° in an aeration chamber to allow dissipation of ethylene
oxide residues.
t4ethod IV:
~--

Unmedicated casting solution was inoculated with 0.2 ml of an
overnight inoculum of S.

aureu~.

The solution was whipped, spread

onto pans, and allowed to dry as above.

The contaminated dry foam was

packaged in aluminum foil laminates provided by the Rexham Corporation
and mailed to International Nutronics, lnc.,a a commercial radiation
sterilizing company.

Cobalt-60 was the source of the gamma radiation

using a total dose of 2.5 t4rads.

After sterilization, the packages

were returned unopened to the laboratory for testing.
Steri 1 i·ty Testing Procedures:
Samples of dry foams sterilized by the four methods above were
tested for sterility.

a.

The USP XVI II method using Fluid Thioglycollate

International Nutronics, Inc., Palo Alto, Cal if.
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Medium (FTM) and Soybean Casein Digest Medium (SCD) was employed.

To

two test tubes each of FTM and SCD were added samples from each method.
The test tubes were allowed to incubate in an incubating oven for 14 days
at 37°.

Also, two positive controls, i.e., tubes of media containing

0.1 ml of an overnight inoculum of S. aureus, and two negative controls
were used for comparison.

Samples of the contaminated dry foams prior

to sterilization by ethylene oxide and radiation were added to additional
~-------t~e-s~t~t~u~b_e_s--o'f~F~T~M--a-n'd~S~C~D-a_n_d.-'in_c_u'b-a~t--e-d.-w~i~t~h~t~h-e--o~t~h-e-r~te-s-·t~m_e_d~i~a-.~---------------_

Samples of the two aseptic preparation methods (Methods I and I I)
were packaged in laminated foil bags and stored at room conditions for
one month.

The samples were then aseptically removed and tested for

ster i 1 i ty.
Miscellaneous Procedures:
The most common defect with laminated aluminum bags is an
ineffective seal.

Thus, fifty bags were sealed with a heat sealer and

totally immersed in water for twenty-four hours.

Upon removal and open-

ing of the bags, none contained moisture indicating that the sealing
procedure was effective.
To determine if the dry foam could withstand normal shipping and
mailing conditions, four samples of unmedicated, uncontaminated dry foam
were packaged in laminated foil and shipped by mail to the East coast
and returned unopened to the laboratory.

The same p-eckages were sent

immediately to a second West coast city and again returned unopened.
These shipped samples were then compared to control samples from the
same batch that were packaged and kept in the laboratory.

CHAPTER I I I
RESULTS
~--

Nitrofurazone StabilJJJL
Table XIV summarizes the average moisture content of packaged

three months' storage at four different storage conditions.

As shown,

the average moisture content of ten samples on the day of manufacture
was 9.7%.
After one month's storage in a refrigerator (+5°; R.H., 55-60%),
freezer (-5°; R.H., 75-90%), and at room conditions (22°; R.H., 50%) the
changes in moisture content were statistically insignificant with the
largest change, i.e., 9.7% to 9.4%, occurring in the freezer.

The

insignificance of these small changes in moisture is not only shown
statistically, but also reflected by the fact that, in all cases, the
nitrofurazone dry foam retained its flexibility, porosity, and nonstickiness.

However, when stored in a dessicator (22°; R.H., 5-6%) for one

month, the moisture content dropped from 9.7% to 7.1% (P < .001) and the
foam became very friable.
After two months' storage in a refrigerator and at room conditions
with an average relative humidity of 47%, no significant changes in
moisture content and gross physical properties were noted.

A drop to

9.5% moisture content occurred in the freezer, but again, this was
n~lible

as the foam still possessed the ideal characteristics.

dessicator, the moisture content dropped from 9.7% on the day of

In the

-

55
manufacture to 8.4% (P

>

.02 < .05) causing the foam to lose its flexi-

b i 1i ty.

No changes in physical properties occurred after three months'
storage in the refrigerator, freezer, and at room conditions (R.H., 48%)
despite the fact that the moisture content of the foam in the freezer
and at room temperature increased to 9.9% while it decreased to 9.2% in
the refrigerator.

These changes are statistically insignificant.

Againt

dessicator with subsequent loss of flexibility.
Table XV lists the zones of inhibition obtained with nitrofurazone dry foam on the day of manufacture and after one, two, and three
months' storage at each of the four storage conditions.

Also included

in the table are the zones of inhibition obtained with the commercially
~vailable nitrofurazone cream.

Storage of the nitrofurazone dry foam at

room conditions, a freezer, and a dessicator for one and two months did
not produce statistically different zones of inhibition from the zones
produced on the day of manufacture.

Samples stored in a refrigerator

for one and two months did, however, produce statistically different
zones as did storage for three months at all four conditions.

These

statistically significant diameters of zones after storage were all
greater than those on the day of manufacture.
Silver

Sulfa~iazine

Stability

'

Table XVI summarizes the average moisture content of packaged
silver sulfadiazine dry foam on the day of manufacture and after one,
two, and three months' storage at the four different storage conditions.
The average moisture content from ten readings on the day of manufacture

~-

~--------

------------- - -

A drop in moisture content from

9~8%

to 9.0% was noted in the

samples stored at room conditions for one month; a slight increase in
porosity occurred, but flexibility was sti 11 maintained.

In the refrig-

erator and freezer after one month, the silver sulfadiazine samples all
retained their original physical
moisture content.

propertie~

despite slight changes in

The samples stored in the dessicator for one month

demonstrated a I os s of mo 1 s ture con tent from 9--:-8% to 9--:-r%; a s Hght
increase in porosity was noted, but flexibility was still maintained.
',,..y

Statistical evaluation showed that these changes were all insignificant.
After two months• storage, all the samples under all the storage
conditions retained their original gross physical properties.

The

samples at room conditions had a drop in moisture content from 9.8% to

9.3% while the samples in the refrigerator, freezer, and dessicator all
gained moisture from 9.8% to 10.2%, 10.0%, and 10.6% respectively.
Again, these changes were statistically insignificant.
Samples stored for three months at room conditions and in the
freezer lost slight amounts of moisture but demonstrated no changes in
physical properties.

After three months in the refrigerator, again the

samples retained their physical qualities despite a slight increase in
moisture content to 9.9%.

Samples in the dessicator lost slightly more

than 1% moisture but still possessed adequate flexibi)ity although they
exhibited a relatively large increase in porosity.

These moisture con-

tent changes were all statistically insignificant.
Table XVI I gives the zones of inhibition obtained with silver
sulfadiazine dry foam on the day of manufacture and after storage under
conditions identical to those for nitrofurazone preparations.

The zones

-
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of inhibition given by the commercially available silver sulfadiazine 1%
cream are also included in Table XVI I.

No statistically significant

differences were noted between the silver sulfadiazine dry foam zones
obtained on the day of manufacture and after one, two, and three months 1
~-

storage regardless of the storage condition with one exception.

After

three months at room conditions, a statistically smaller mean zone of
inhibit1on was produced (P < .001).
Results of Sterilization of Dry Foam
Method 1:
Sterilization of the inoculated casting solution by autoclaving
did not produce any changes in its consistency and spreadability during
the subsequent aseptic preparation of the dry foam.
also did

~ot

show any physical changes.

The final product

Samples of the dry foam so

prepared did not show any growth on incubation in the two media used
to test their sterility.

The positive controls showed growth while

the negative controls showed no growth.
Method I I :
Filtration of the inoculated casting solution also did not
alter the c6nsistency and spreadabil ity of the whipped foam and/or the
physical properties of the final product.

Aseptic preparation of the

dry foam produced a sterile product as no growth occurred after fourteen days 1 incubation.

Both negative controls of each medium also

exhibited no growth while the positive controls did.
Samples of dry foam prepared by Methods I and I I above and
aseptically packaged in laminated aluminum foil were tested for

~-

~~~~-

~

~

~~~

~

~

--~----------

sterility after storage for one month at room conditions.

These

samples also showed sterility despite the fact that the insides of the
foil packages were only cleaned by wiping with 70% isopropanol (rubbing
alcohol).
11ethod I II :
Samples of inoculated dry foam prior to ethylene oxide sterilization showed growth in the media used.

Separate samples of foam after

ethylene oxide sterilization showed sterility.

However, after the

sterilization-aeration cycles were completed, the foam showed physical
deterioration such as Joss of flexibility and increase in porosity.
Method IV:
The irradiation sterilized samples of dry foam also met the
test for sterility.

Freshly inoculated samples prior to sterilization,

as expected, showed growth.

Some loss of flexibility of the foam

after irradiation sterilization was observed.

However, this loss was

not significant enough to affect the desirable features of the product.
Results of

Shi~~

Comparison of the shipped samples and controls kept in the
laboratory showed that there was no loss of desirable features of flexibility and porosity on shipping.

-

~-

CHAPTER IV
DISCUSSION
~-

Conventional topical dosage forms consist of solutions, lotions,
creams, oir{tments, and aerosols.
widel

While these types of products are

used, they are not without some inherent_d_i_s_ad_v_ao_t_a_ge_s_s_ucb_as._______

necessity for removal, waste especially from aerosols, and possible
aggravation of open lesions vfa inunction.

Because of

thes~

disadvan-

tages, a novel topical dressing which would dissolve on moist skin,
release the active ingredient without inunction, and not necessitate
removal was developed (1-3).

However, this dressing had its own

disadvantages; the most significant being loss of moisture and flexibility
prior to and during storage.

Therefore, the use of a moisture impermeable

package and determination of suitable storage conditions were necessary.
Because of the inexpensiveness and great versatility of plastics,
a twelve week storage study was designed using what was thought to be a
moisture proof plastic bag (see Table I I 1).

After twelve weeks of

storage in a refrigerator with periodic evaluation of

moist~re

content,

it was found that the dry foam gained moisture and became very sticky
and difficult to handle.
just four weeks.
data.

In a freezer, the foam liquified completely in

Storage at room conditions produce'cl very inconsistent

An increase in moisture content occurred after two and three

weeks' storage while a decrease occurred after four weeks.

Similarly,

six weeks' storage showed increased moisture content while eight and
twelve weeks' caused decreased moisture content.

These room condition
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samples maintained good flexibility without acquiring a tacky feeling.
The results of this study

confi~med

that the dry foam was sensitive to

moisture and indicated that the plastic bags were permeable to moisture.
Consequently, a four week storage study employing plastic bags
lined with waxed-paper and parchment paper as well as double-bagging was
initiated to determine if these liners or double thickness bags would
minimize moisture permeation (see Table IV).

With waxed-paper or double

bagging, moisture content dropped sufficiently to cause loss of flexibility in samples stored at room conditions; samples packaged with
parchment liner also lost moisture, but flexibility was maintained after
one, two, three, and four weeks.

3r

All samples stored at

lost moisture

and flexibility regardless of the type of 1 iner or double bagging, even
.after only one week of storage.

Freezer samples, again regardless of

the type of package, gained sufficient moisture after three and four
weeks to cause tackiness such that the foam could not be easily handled;
samples stored in a refrigerator all maintained adequate flexibility
without tackiness after four weeks.
One would expect that if the foam gains or loses

moi~ture

at a

particular storage condition, such a change would be steady and consistent.

That is, if a gain were noted after one week storage, then a

drop in moisture after two or three weeks should not occur.
this was not the case, especially

a~

room conditions.

However,

These inconsistent

data (see Tables I II and IV) indicated that some other factor besides
temperature and type of package was also playing an important role in the
physical stability of the foam.

This factor was finally determined to be

relative humidity which, of course, changes from time to time, not only
at room conditions, but also in refrigerators and freezers.

Although

-
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Tables I II and IV indicate relative humidity at the various storage
conditions, this was not monitored during these two preliminary studies
because It wasn•t anticipated that relative humidity would be a significant factor.
~-

These results showed that 1) the plastic bags· ·were permeable, .2)
both temperature and relative humidity during storage must be controlled,
and 3) the original formula might be improved to produce a more stable
ry foam.

As stated earlier, a significant drop in moisture content

would cause a loss of flexibility while an increase may cause the foam
to be too tacky.

Of these two possibilities, loss of flexibility is the

more important because an inflexible dressing cannot be applied to
anatomical areas that have nonplanar geometry.

Although a tacky product

could be applied to body areas, its hand! ing may require forceps or it
may adhere to the package.
The loss of flexibility may be attributed to crystallization of
sorbitol occurring on loss of water.

Glycerin in varying concentrations

was used as a second humectant and an adjunct to maintain sorbitol in
solution, resulting in a more pliable foam.

Packaging material other

than plastic bags would also be required to maintain moisture content of
the foam.

Laminated aluminum foil was selected since it would be the

most satisfactory moisture proof package.

Consequently, foil laminates

were used during the remainder of the study.
Three different dry foam formulas containing nitrofurazone and
silver sulfadiazine were manufactured, packaged in the foil bags, and
stored for one week at the two extremes of relative humidity, freezer
{R.H., 75-90%) and dessicator {R.H., 5-6%).
listed in Tables V and VI.

These modified formulas are

Moisture content on the day of manufacture

~~~~~

~

---------~----~

-
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and after storage as wei 1 as subjective comments regarding physical
properties are summarized in Tables Vl1 and VI I I.

Comparison of the

three modified formulas with the original, showed that formulas II and
I I I became very tacky after one week in the freezer, and exhibited a
slight Joss in flexibility and an increase in por6sity in the dessicator.
Formula IV, while less tacky than formulas I I and I I I, was more sticky
than the original.

After storage in the freezer, the tackiness of formula

IV was relatively satisfactory, but not ideal.

Both the original formula

and formula IV showed slight losses of flexibility and increases in
porosity after storage in the dessicator.

Changes in physical properties

would appear to be directly related to changes in moisture content.

In

fact, this was the major assumption and reason for finding a moisture
impermeable package and for defining exact storage conditions with
respect to relative humidity and temperature.

~-

However, study of formulas

II through IV showed that this was not the entire picture, but that
factors other than moisture content also cause physical changes on
storage.

Formulas I I-IV as well as the original formula did not gain or

'

lose significant amounts of moisture when packaged in foil and yet, they
exhibited unsatisfactory changes in physical properties.

To explain

these changes is difficult, but they apparently are inherent in the
formula.
Because formulas I I-IV exhibited unsatisfactqry physical changes,
additional formulas, V-VI I, with decreasing concentrations of glycerin
were prepared.

These additional formulas are listed in Tables IX and X.

They were evaluated for physical properties on the day of manufacture
and then packaged in foil and stored for one week at room conditions, in
a freezer, a refrigerator, a dessicator, and an oven set at 37°.

Because
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the previous study showed that the foil bags were very satisfactory in
preventing moisture content changes, the purpose of this work was only
to find a more suitable formula that did not possess the unknovm,
inherent factors alluded to earlier.

A more suitable formula would be
~=

defined as one yielding a nonsticky, flexible product just as the
original but which also contained some glycerin to help maintain flexibility.

The tackiness of formulas I I-IV was caused by excess glycerin.

A-formu iaw1Tnfhe correct concentration of g 1ycer in may not possess
this unde5irable tackiness while it might retain greater flexibility than
the original, nonglycerin formula.

Tables XI and XI I summarize the

physical properties of the original

form~la

formulas V-VII.

and the additional modified

Formulas V and VI showed simi Jar results as formulas

II-IV; that is, too tacky in the freezer and loss of flexibility in the
dessicator.

All the formulas were totally deteriorated in an oven

environment and exhibited varying changes in the refrigerator and at room
conditions .. Of all the formulas, formula VII, i.e., the formula with the
least amount of glycerin,

was most satisfactory on the day of manufac-

ture as well as after storage at the various conditions excepting the
oven.

For this reason, it was chosen as the most suitable formula for

further evaluation.
The preliminary work indicated that laminated aluminum foil bags
appeared to be a suitable package, that temperatures
ture caused physical rnstability of

th~

~bove

room tempera-

packaged foam, and that a Joss

of flexibility was not always associated with losses in moisture content.
Also, preliminary studies indicated that proper storage conditions must
be defined in terms of relative humidity as well as temperature.
As discussed earlier, a stable product must maintain potency and

64

'
utjlity after it has been packaged and stored for prolonged periods.
determine the stability of the foam as far as

shelf~life

To

and marketing

potential were concerned, a three month storage study was conducted with
stability evaluated at one month intervals according to physical
properties, moisture content changes, and potency as determined by the
semiquantitative microbiological assay.
On the day of manufacture, nitrofurazone foam was very flexible,
not sticky, and dlssoived on moist skinwitnTn-fTfteen seconds; these
properties make it a very useful dressing for traumatized and infected
skin.

On the day of manufacture, moisture content was 9.7%.

After one,

two, and three months' storage in a refrigerator, freezer, and at room
conditions, the moisture content varied insignificantly (P > 0.3) and
the foam retained its original physical properties.

However, in a

dessi~ator, the moisture content decreased significantly (P < .05 > .001)

and the foam lost flexibility.

The data in Table XIV show that the pack-

age is a suitable container for storage at high humidities as it
prevented the foams from gaining excess moisture which would have caused
them to become too tacky and difficult to handle.

At low

humiditi~s,

however, the package did not prevent the foam from losing moisture.
Preliminary work showed some formulas wi 11 lose flexibi 1 i ty without a
corresponding decrease in moisture content, suggesting that some unknown
inherent factors lrJere causing the foam to lose flexibility.

However, in

this three month study, the loss of flexibility was associated with a
significant loss of moisture; this indicates that the modified formula,
i.e., VI I, does not in itself contribute to loss of flexibility.
th~

Why

moiiture impermeable foil bags were not effective in preventing loss

of moisture is elusory.

Speculation would lead one to believe that

,_;
~-
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either the seals were ineffective or that the foil bags are not really
impermeable.

Because the sealing procedure was shown to be effective

and samples stored at high humidities did not gain moisture, these
speculative reasons can probably be eliminated.

In general, the only
~--

conclusion one can make frtim these data is that a relative

humidi~y

bf

S-6% Will cause nitrofurazone dry foam to lose moisture and flexibility
even when packaged in foil laminates.
To determine if the storage conditions, time, and/or the package
caused any deterioration of the drug in the foam or to determine if the
vehicle itself inactivated the drug, a microbiological assay was done.
A product must retain at least 90% of the labelled potency after storage
for prolonged periods if it is to be accepted as therapeutically
efficacious.

Table XV shows the zones of inhibition both for the nitro··

furazone foam and the commercially available nitrofurazone cream obtained
on the day of manufacture and after one, two, and three months 1 storage
at the four storage conditions.

Storage of the nitrofurazone dry foam

at room conditions, freezer, and a dessicator for one and two months did
not produce statistically different diameters of zones from those
produced on the day of manufacture.

Samples stored in a refrigerator

for one and two months, however, did produce statistically different
zones as did storage for three months at alI four conditions.

These

statistically different zones after storage were alI greater than those
on the day of manufacture.

To explain these differences is difficult

although two possibilities exist.

One is that refrigeration conditions

or long storage causes some interaction to occur between nitrofurazone
and one of the components of the vehicle (e.g., Miranol) such that a
greater release occurs;

What this interaction might be cannot be
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ascertained at this time.

However, when comparing differences between

zones after one and two months with zones after three months, there is
no significant difference and this fact casts a doubt on the possibility
of an interaction resulting in increased release.
tion involves the manufacturing process.

The second explana-

All the samples were from the

same .batch, but not necessarily from the same pans.

Because some pans

became slightly warped from use, a difference in the thickness of the
foam between pans and even within the same pan may have occurred; also,
differences in bubble size may have occurred since it was not very easy
to obtain a consistent and uniform spreading procedure.

Thus, samples

which were thict<er or had small bubbles would have contained more active
ingredient and produced larger zones; similarly, thinner samples or
samples with larger bubbles would produce smaller zones.

This second

possibility seems much more likely to explain the statistical differences
observed with the nitrofurazone dry foam.
On the day of manufacture, silver sulfadiazine foam was also
very flexible, not sticky, and dissolved nn moist skin in fifteen
seconds.

Table XVI summarizes the moisture contents on the day of

manufacture and after one, two, and three months 1 storage at the four
storage conditions.

Silver sulfadiazine dry foam packaged in laminated

aluminum foil bags and stored for three months in a freezer, refrigerator, and at room conditions showed similarities with nitrofurazone foam;
...

that is, physical properties and moisture content demonstrated
statistically insignificant changes after one, two, and three months

1

storage.

Storage in a dessicator produced surprisingly interesting

results.

It would be expected from the nitrofurazone results that the

silver sulfadiazine stored in a dessicator would also lose moisture and

L_

~-
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flexibility.

However, this was not the case at all; after one, two, and

three months' storage, moisture content was statistically unchanged and
flexibility was maintained.

Because identical procedures with respect

to manufacturing) packaging, storage, and evaluation were employed for
both the nitrofurazone and silver sulfadiazine dry foams, the different
results can only be attributed to the active ingredients- namely that
silver sulfadiazine somehow aids in retaining moistu;·e and flexibility
while nitrofurazone

do~s

not.

Other active ingredients may very well

exhibit similar types of effects and this must be considered during any
future drug evaluations.
As with nitrofurazone, potency as a guide to stability of silver
sulfadiazine dry foam, was determined by comparing the zones of inhibition
on the day of manufacture and after one, two, and three months' storage.
Tab 1e XV II shows the zones for both the foam and the commercia 11 y ava i 1able cream.

Samples stored for one and two months at all four conditions

produced zones of inhibition which were statistically insignificant from
the zones obtained on the day of manufacture.

Three months' storage in

a refrigerator, freezer, and dessicator also did not affect the potency
of the dry foam while samples stored at room conditions for three months
produced statistically smaller zones (P
"

of manufacture.

<

.001) when compared to the day

While the possibility that three months' storage at

·room conditio~s could have caused a loss of potency, this difference was
more likely due to variations in sample thickness and/or bubble size as
discussed earlier.
For use on open, infected lesions, use of a sterile product is
desirable.

Sterilization of the dry foam could easily be achieved by

three of the four methods employed.

Aseptic methods produced a sterile
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product substantiated by no growth in the two accepted test media, fluid
thioglycollate medium and soybean casein digest medium.

Growth occurred

in the positive controls which indicated that the media and incubation
conditions were conducive to microbial growth.

Because aseptic prepara~-

tion requires strict adherence to technique procedures and is always
subject to accidental contamination, even if good technique is employed,
sterilization of the final, packaged product is more advantageous from a
manufacturer's viewpoint.
Ethylene oxide is widely used to sterilize products which cannot
be autoclaved and which can be packaged in ethylene oxide permeable
containers, namely plastics.

Even though this product must be packaged

in foil, it could be packaged first in plastic, exposed to ethylene
oxide, and then packaged as a double bag with a laminated aluminum foil
bag as the outer container.

For this reason, contaminated foam was

packaged in plastic and sterilized in a cold ethylene oxide cycle, i.e.,
~-

29° for three hours, followed by aeration for eight hours at 63°.

Upon

removal of the foam, it was noted that all. flexibility was lost; the
product was friable and crumbled easily.

It was felt that this was due

to the temperature employed in the aeration cycle and not due to a direct
ethylene oxide chemical reaction.

Even though sterility was achieved as

shown by no growth in the testing media, the deteriorating effects of
the

~eration

cycle excludes ethylene oxide as a method of sterilizing

this product.
Method IV, gamma irradiation, is the method of choice for products
packaged in laminated aluminum foil.

Packaged samples which were exposed

to radiation conditions were indeed rendered sterile as no growth was
noted in the testing media; just as important was the fact that the foam
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retained adequate flexibility and

~tility.

Thus, this method provides a

very practical, inexpensive, and efficient means to sterilize the
packaged dry foam.

It should be mentioned that all the methods of ster-

ilization were performed

~n

unmedicated samples.

Thus, radiation will

not be a useful method if the drug or drugs incorporated into the foam
are destroyed or undesirably altered by radiation.
In order to determine if the foam could withstand normal shipping

East Coast and returned unopened to the laboratory.

The same packages

were sent immediately to a second West Coast city and again returned
unopened.

These samples which were exp6sed to common mail handling were

opened and compared to samples kept in the laboratory.

No adverse

changes were noted in the shipped samples as they alI retained their
original flexibility and in general, showed that the product could very
satisfactorily withstand any conditions of shipping and mailing.

-

CHAPTER V
SUMMARY AND CONCLUSIONS
A highly water soluble, flexible dry foam was recently developed
(1-3).

The dry foam dissolves quickly on moist skin and releases the

active ingredient without inunction.

HQw_eiLe_r_,_tbe_£oam_Ls-sens-L1.:.-i-~e-to'---------c

moisture such that a loss of moisture causes the foam to lose flexibility
while a gain causes it to adhere to the package or liquefy when touched.
The objectives of this study were to 1) modify the formula to
minimize moisture sensitivity, 2) determine a suitable package, 3)
determine proper storage conditions,

4) determine shelf-life of nitro-

furazone and silver sulfadiazine dry foams, and 5) det.ermine a suitable
sterilizing procedure since the dry foam is intended for use on open,
infected lesions.
Six different modified formulas were made and compared to the
original.

Glycerin, in varying concentrations, was used as the modify-

ing agent since its humectant properties would help retain moisture and
hence, flexibility.

Comparison of the six formulas showed a glycerin

concentration of 0.19% wet weight produced the most satisfactory dry
foam with respect to flexibility, nonstickiness, dissolution time, and
porosity.

Using this modified formula, the remaining objectives were

accomplished.
Plastic bags and plastic with liners proved unsatisfactory as a
packaging material as they were permeable to moisture.

On the other

hand, samples of dry foam packaged in laminated aluminum foi 1 bags and

~-
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stored at room conditions, in a refrigerator, and in a freezer, did not
gain or lose moisture.
of

moistur~

However; aluminum laminates did not prevent loss

and flexibility in samples

sto~ed

i.e., 3r,or low humidities, i.e., 5-6%.

at elevated temperature,

Because the latter storage

conditions are impractical, the unsatisfactory results are only academic.
Consequently, laminated aluminum foil bags provide a suitable packaging
material for the dry foam.
Wnrie storage at room conditions and in a freezer indicated the
dry foam was physically stable for at least three months, refrigerat1on
conditions appeared to be most satisfactory.

Both temperature and

relative humidity will physically alter the dry foam and these parameters
can best be controlled in a refrigeration environment.

Thus, 5° with a

relative humidity of 55-60%, the usual refrigeration conditions, are
recommended for storage of the dry foam.
The study also indicated that the foam can physically withstand
common shipping and mailing procedures; thus, mailing of the final
product does not pose any problems.
Potency of nitrofurazone and silver sulfadiazine dry foams was
not significantly affected by any component of the vehicle, by the
package, or by any of the storage conditions including the two extremes
of relative humidity, 75-90% and 5-6%.

Thus, at least.these two drugs

can be incorporated successfully into the dry foam.

This suggests that
....

the dry foam might be a satisfactory vehicle for other commonly used
antimicrobials.
Sterilization with ethylene oxide causes the foam to lose
flexibility and thus, this method cannot be used.

While aseptic prepara-

tion employing autoclaving or filtration of the casting solution produced

~-

--------------------
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a sterile product, the best method, with respect to expense, practicality,
and efficiency, was sterilization by gamma irradiation.

This method

allows the final package~ product to be steri I ized without phys leal
degradation.

Gamma irradiation is therefore recommended as the steril-

ization procedure provided the active ingredients are not undesirably
affected by radiation.

'-~

~-
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